Introduction {#s1}
============

Spatial compartmentalization of RNA is central to many biological processes across all kingdoms of life, and enables diverse regulatory schemes that exploit both coding and noncoding functions of the transcriptome. For example, the localization and spatially restricted translation of mRNA plays a fundamental role in a wide variety of biological contexts, including asymmetric cell division in bacteria and yeast, body-pattern formation in *Drosophila* and *Xenopus*, and signaling at mammalian neuronal synapses ([@bib32]). Moreover, the localization of noncoding RNAs (ncRNAs) can play an architectural role in the assembly of subcellular structures, most notably within the nucleus, wherein ncRNAs help to assemble short-range chromatin loops, higher-order chromatin domains, and large sub-nuclear structures like nucleoli and Barr bodies, among others ([@bib62]; [@bib19]). However, despite these examples, our general understanding of the breadth and biological significance of RNA subcellular localization remains inchoate.

Techniques that elucidate the subcellular localization of RNAs are therefore critical for advancing our understanding of RNA biology. Classically, such techniques rely either on imaging or biochemical fractionation. Imaging methods---such as Fluorescence In Situ Hybridization (FISH) and RNA reporter systems---are powerful tools for elucidating the positions of a small number of target RNAs at low-to-moderate throughput ([@bib71]; [@bib10]; [@bib56]; [@bib26]; [@bib53]; [@bib44]; [@bib22]). Alternatively, unbiased approaches for RNA discovery couple biochemical manipulations to microarray or deep sequencing analysis. For example, the RNA partners of proteins with characteristic subcellular localization can be identified through techniques that couple protein immunoprecipitation to RNA-Seq ([@bib70]; [@bib23]). Such methods have revealed the localization of many mRNAs, in addition to discovering novel non-coding RNAs involved in RNA splicing ([@bib12]) and RNAi ([@bib51]). On a broader scale, a deep sampling of RNAs residing within a cellular compartment---for example, an intact organelle of interest, or partitions along a sucrose gradient---can be identified by coupling subcellular fractionation to microarray analysis ([@bib18], [@bib17]; [@bib45]; [@bib68]; [@bib6]; [@bib50]; [@bib59]; [@bib11]) or to RNA-Seq ('Fractionation-Seq,' [@bib66]; [@bib48]). These powerful methodologies facilitate a deep characterization of the transcriptome of a subcellular target, in cases where a robust fractionation protocol for that target can be developed, and can sometimes be applied to native cells or tissues ([@bib17]).

Despite this progress, some technological gaps exist among current methods for studying RNA localization. Imaging approaches are of limited throughput, and may require specialized reagents, constructs, or microscopes that are only accessible to a handful of laboratories ([@bib71]; [@bib10]; [@bib56]; [@bib26]; [@bib53]). The efficacy of immunoprecipitation-based approaches is highly sensitive to the antibodies and enrichment protocols used ([@bib25]) and captures only RNAs that are directly complexed with each target protein. Fractionation-Seq is applicable only to organelles and subcellular fractions that can be purified, and---like all fractionation-based methods---can be complicated by contaminants and loss of material ([@bib39], [@bib43]). Therefore, new technologies are needed for unbiased and large-scale discovery and characterization of RNA *neighborhoods,* with high spatial specificity, and within cellular structures that can be difficult to purify biochemically.

Here we introduce such a technology---termed APEX-RIP---that enables unbiased discovery of endogenous RNAs in specific cellular locales. APEX-RIP merges two existing technologies: APEX (engineered ascorbate peroxidase)-catalyzed proximity biotinylation of endogenous proteins ([@bib61]), and RNA Immunoprecipitation (RIP; [@bib23]). We demonstrate that APEX-RIP is able to enrich endogenous RNAs in membrane-enclosed cellular organelles---such as the mitochondrion and nucleus---and in membrane-abutting cellular regions---such as the cytosolic face of the endoplasmic reticulum---although its applicability in completely unbounded compartments appears more limited. The specificity and sensitivity of this approach are higher than those obtained by competing methods. Moreover, by applying APEX-RIP to multiple mammalian organelles, we have generated high quality datasets of compartmentalized RNAs that should serve as valuable resources for testing and generating novel hypotheses pertinent to RNA biology. Given its ease of use and scalability across subcellular compartments, we anticipate that APEX-RIP will provide a powerful new tool for the study of RNA localization.

Results {#s2}
=======

Development of APEX-RIP and its application to mitochondria {#s2-1}
-----------------------------------------------------------

APEX is an engineered peroxidase that can be targeted by genetic fusion to various subcellular regions of interest ([@bib61]) ([Figure 1A](#fig1){ref-type="fig"}). Upon addition of its substrates---biotin-phenol (BP) and hydrogen peroxide (H~2~O~2~)---to live cells, APEX catalyzes the formation of biotin-phenoxyl radicals that then diffuse outward and covalently biotinylate nearby endogenous proteins. More distal proteins are not significantly labeled because the biotin-phenoxyl radical has a half-life of less than one millisecond ([@bib73]). Previous work has shown that APEX-catalyzed proximity biotinylation, coupled to streptavidin enrichment and mass spectrometry, can generate proteomic maps of the mitochondrial matrix, intermembrane space, outer membrane, and nucleoid, each with \<5 nm spatial specificity ([@bib61]; [@bib29], [@bib28]; [@bib24]).

![APEX-RIP in mitochondria.\
(**A**) Overview of the APEX-RIP workflow. Live cells expressing APEX2 (grey 'pacmen') targeted to the compartment of interest (here, the mitochondrial matrix) are incubated with the APEX substrate biotin-phenol (BP; red B: biotin). A one-minute pulse of H~2~O~2~ initiates biotinylation of proximal endogenous proteins ([@bib61]), which are subsequently crosslinked to nearby RNAs by 0.1% formaldehyde. Following cell lysis, biotinylated species are enriched by streptavidin pulldown, and coeluting RNAs are analyzed by qRT-PCR or RNA-Seq. IMM: inner mitochondrial membrane. (**B**) Imaging APEX2 biotinylation in situ. HEK 293T cells expressing V5-tagged mito-APEX2 were biotinylated using the APEX-RIP workflow, fixed, and stained as indicated. The bottom row is a negative control in which H~2~O~2~ treatment was omitted. Scale bars, 10 µm. TOM20 is a mitochondrial outer membrane protein; neutravidin staining detects biotinylation. (**C**) In situ biotinylation of the mitochondrial matrix proteome requires mito-APEX2, BP, and H~2~O~2~. Streptavidin blot analysis of whole cell lysates prepared following the protocol described in (**A**), or after omitting components of the APEX reaction. Arrowheads denote endogenous biotinylated proteins ([@bib8]). Anti-V5 blot (*bottom*) detects expression of mito-APEX2. (**D--E**) mito-APEX-RIP efficiently recovers the mitochondrial transcriptome. (**D**) Gene-level RNA-Seq analysis of mito-APEX-RIP; data are the average values of three experimental replicates. Fold change is defined as (FPKM~post-enrichment~/FPKM~pre-enrichment~); dashed lines indicate significance thresholds for fold enrichment (determined by ROC analysis, see Materials and methods) and *p-*values calculated by CuffDiff2 ([@bib69]). Mitochondrial genomes encode 13 mRNAs, two rRNAs and 22 tRNAs (*red*). Note that three mitochondrial tRNA genes, MT-TH, MT-TL2, and MT-TG, were also enriched. See [Supplementary file 1A](#supp1){ref-type="supplementary-material"}. (**E**) Nucleotide-level RNA-Seq analysis of mito-APEX-RIP, mapped to the human mitochondrial genome (innermost circle). Outermost circle: reads from the full APEX-RIP protocol; middle circle: reads from the negative control. Note the enrichment of several mitochondrially-encoded tRNAs and the D-loop leader transcript. Ribosomal RNAs were removed during library preparation (see Materials and methods). See also: [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"},[2](#fig1s2){ref-type="fig"}.](elife-29224-fig1){#fig1}

Because most cellular RNAs exist in close proximity to proteins, we reasoned that APEX-tagged subcellular proteomes could also provide access to the nearby subcellular transcriptomes by crosslinking labeled proteins and RNA together in situ ([Figure 1A](#fig1){ref-type="fig"}). As our first target organelle for this approach, we selected the mitochondrion because its RNA content---derived from both the mitochondrial genome and from imported, nuclear-encoded RNAs---has been extensively characterized by a wide array of complementary methods ([@bib48]; [@bib2]; [@bib58]; [@bib63]), hence providing a 'gold-standard' to which we can compare our results. The mitochondrial matrix was also the first mammalian compartment mapped by APEX proteomics methodology ([@bib61]). As an RNA-protein chemical crosslinker, we opted for mild formaldehyde treatment, which covalently captures most protein-protein and protein-nucleic acid interactions, and can be achieved with minimal disruption of native interactions in live cells. It is for these reasons that formaldehyde is used in several RIP technologies aimed at identifying the RNA partners of specific proteins of interest, including our own 'fRIP-Seq' protocol ([@bib13], [@bib25]).

Since it was unclear *a priori* whether APEX-catalyzed biotinylation should precede or follow the formaldehyde crosslinking step, we explored both schemes in parallel ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}; see Materials and methods). Each protocol, applied to HEK 293T cells that transiently expressed mitochondrially-localized APEX ('mito-APEX,' [Supplementary file 5A](#supp5){ref-type="supplementary-material"}), resulted in clear enrichment of fifteen mitochondrial-encoded RNAs---relative to the cytosolic marker *GAPDH*---as gauged by qRT--PCR (average of 49.3 ± 3.5 and 60.9 ± 4.1 fold enrichment, respectively, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We next proceeded to RNA-Seq analysis, assuming that fixing cells prior to biotinylation would better capture transient or weak RNA--protein interactions, and therefore selecting the crosslinking-then-BP protocol (see Materials and methods). However, since it was unknown whether biotin-phenoxyl radicals might cleave or modify RNA in a manner that introduces bias into deep-sequencing libraries ([@bib76]), we chose to prepare these libraries using the 'Ribo-Zero' method, which physically removes ribosomal RNAs prior to fragmentation and sequencing adaptor ligation (Materials and methods). Since this workflow does not require the presence of a 3´--poly(A) tail for first-strand synthesis, it offers superior coverage in cases with lower input quality ([@bib1]), and furthermore enables sampling of a broader range of RNA classes.

Deep-sequencing of mito-APEX-RIP libraries confirmed that mitochondrial mRNAs were substantially enriched over the majority of nuclear-encoded genes. However, a sizeable 'shoulder'---comprising a number of conspicuous off-target RNAs---was also unexpectedly observed ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}). To address this issue, we re-examined our labeling and crosslinking protocols, using a sampling of these off-target RNA markers (e.g., the abundant nuclear RNA *XIST,* and cytosol-localized RNAs *HOOK2* and *MAN2C1*) as more incisive negative controls. We furthermore employed HEK293T cells that stably expressed mitochondrially-localized APEX2 (mito-APEX2, [Figure 1B--C](#fig1){ref-type="fig"}, [Supplementary file 5A-B](#supp5){ref-type="supplementary-material"}), a more active APEX variant that we hypothesized might improve target enrichment ([@bib37]). This improved construct, and more controlled analysis revealed that APEX labeling followed by crosslinking provides superior specificity, improving the average enrichment of target RNAs---relative to the contaminant RNAs identified above---by nearly ten-fold ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). We suspect that the mild formaldehyde treatment compromises membrane integrity ([@bib21]), allowing BP radicals to escape to adjoining compartments when APEX labeling is performed after, rather than before, formaldehyde treatment.

Using the optimized APEX-first/crosslinking-second protocol, we then mapped the mitochondrial transcriptome of mito-APEX2-expressing HEK 293T cells by RNA-Seq ([Figure 1D](#fig1){ref-type="fig"}, [Supplementary file 1B](#supp1){ref-type="supplementary-material"}). Gene-level analysis comparing fold enrichment and statistical significance of all human genes (Materials and methods) revealed that all 13 mRNAs and both rRNAs encoded by the mitochondrial genome were highly enriched (greater than 11-fold; [Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Supplementary file 1A](#supp1){ref-type="supplementary-material"}). Surprisingly, we even observed the enrichment of several mitochondrial-encoded tRNAs, although our library preparation workflow generally excluded such smaller RNA species ([Figure 1D](#fig1){ref-type="fig"}). Read density plots mapped to the mitochondrial genome demonstrated that most of our captured RNAs correspond to fully-processed transcripts, including mRNAs, interstitial tRNAs, and the D-loop leader sequence from which mitochondrial transcription initiates ([Figure 1E](#fig1){ref-type="fig"}). Intriguingly, mito-mRNA read densities appeared to correlate with previous measures of mRNA half-life ([@bib52]). For example, mRNAs encoding MTCO1-3 have longer half-lives, and more reads from APEX-RIP, than mRNAs encoding MTND1-2. We therefore conclude that APEX-RIP is a specific and sensitive approach for mapping the transcriptome within a membrane-bound organelle.

APEX-RIP mapping of nuclear-cytoplasmic RNA distribution {#s2-2}
--------------------------------------------------------

Having established that APEX-RIP in the mitochondrion, we next turned our attention to a more challenging compartment: the mammalian nucleus. The nucleus is more complex and has a less well-defined transcriptome than the mitochondrial matrix, but previous Fractionation-Seq datasets from HEK 293T ([@bib67]) again provide a reference list to which we can compare our results.

We generated HEK 293T cells that stably express APEX2 in the nucleus (APEX-NLS) or in the cytosol (APEX-NES, where NES is a Nuclear Export Signal) ([Supplementary file 5A](#supp5){ref-type="supplementary-material"}). The specificity of in situ biotinylation by these constructs within each compartment was confirmed by imaging ([Figure 2A](#fig2){ref-type="fig"}, [Supplementary file 5B](#supp5){ref-type="supplementary-material"}). Whole cell lysates prepared from each cell line also produced distinct 'fingerprints' of biotinylated proteins, as assayed by streptavidin blotting ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![APEX-RIP mapping of the nuclear-cytoplasmic RNA distribution.\
(**A**) Fluorescence imaging of nuclear and cytosol-targeted APEX2 fusion constructs. HEK 293T cells expressing the indicated constructs ('NLS,' nuclear localization signal; 'NES,' nuclear export signal) were labeled with biotin-phenol, crosslinked and stained as indicated. Scale bars, 10 µm. DAPI is nuclear stain. (**B**) APEX-RIP recovers known nuclear and cytosolic standard RNAs, defined here as long noncoding RNAs (nuclear markers, *blue*) and RNAs proximal to the Endoplasmic Reticulum (cytoplasmic markers,*red*---defined by ([@bib31]), with measured *p*-values≤0.05---see Materials and methods). *Top*: APEX2--NLS-RIP enriches nuclear standards. *Middle:* APEX2--NES-RIP enriches cytoplasmic standards. *Bottom:* Combined analysis of the APEX2--NLS and APEX2--NES RIP experiments distinguish the two classes. Fold changes are defined as (FPKM~post-enrichment~/FPKM~pre-enrichment~); combined fold change as \[FPKM~NLS--post-enrichment~ /FPKM~NES--post-enrichment~\]. Dotted line indicates the significance threshold for nuclear localization. (**C**) Global analysis of nuclear and cytoplasmic RNA localization by combined APEX2-NLS and APEX2-NES RIP. Vertical dashed lines indicate the cutoffs for nuclear and cytosolic RNAs. Horizontal dash line indicates *p*-value=0.05. Top histogram illustrates the distribution of RNAs with *p*-value=5×10^−5^, which are boxed in gray in the scatter plot. The average of data from three biological replicates are shown. See [Supplementary file 2A-B](#supp2){ref-type="supplementary-material"}. (**D**) APEX-RIP reveals classes of RNAs with canonical and noncanonical nuclear-cytoplasmic distributions. Left: the same data as in (**C**), separately parsed into mRNAs (*top*) and lncRNAs (*bottom*). Right: read density plots of example RNAs from each class that exhibit stereotypical and atypical localization. *EEF1A1* and *C1orf63* are mRNAs; *XIST* and *SNHG5* are lncRNAs. For each gene, a common y-scale is used for all read tracks. SnoRNAs encoded in the *SNHG5* gene body are indicated as gray rectangles. (**E**) Venn diagrams comparing APEX-RIP and fractionation-based RNA datasets ([@bib67]). (**F**) Nuclear APEX-RIP is more sensitive than is biochemical fractionation. *Left:* Specificity of the APEX-RIP and nuclear RNA datasets ([@bib67]). Off-target RNAs were defined as actively translated ER-proximal mRNAs ([@bib31]). *Right:* Recall of nuclear standard RNAs, defined as a set of 827 lncRNAs annotated by GENCODE hg19 with average pre-enrichment FPKM ≥ 1.0. See also: [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}--[2](#fig2s2){ref-type="fig"}.](elife-29224-fig2){#fig2}

We performed APEX-RIP on both APEX-NLS and APEX-NES cells, using the biotinylation-first/crosslinking-second protocol established above, with an additional one-minute radical-quenching step in between the APEX and crosslinking steps ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; see Materials and methods). Encouragingly, 'gold standard' nuclear and cytosolic RNAs were enriched from the corresponding cell lines as predicted: long non-coding RNAs, which are predominantly nuclear, were enriched in APEX-NLS-RIP and de-enriched in APEX-NES-RIP ([Figure 2B](#fig2){ref-type="fig"}, *top*), while endoplasmic reticulum-proximal mRNAs ([@bib31]) exhibited the converse profile ([Figure 2B](#fig2){ref-type="fig"} *middle*). As a further test, we directly compared the enrichments from APEX2-NLS and APEX2-NES to one another, confirming that they had effectively parsed known nuclear- and cytosol-localized RNAs into the expected compartments ([Figure 2B](#fig2){ref-type="fig"} *bottom *and C). We used Receiver Operating Characteristic (ROC) analysis to obtain final transcript lists of 5740 nuclear RNAs and 5367 cytosolic RNAs, with observed contamination frequencies (i.e. the ratio of enriched off-target RNAs to total enriched RNAs) of \<1.6% and \<1.5%, respectively ([Supplementary file 2A-C](#supp2){ref-type="supplementary-material"}, [Figure 2---figure supplement 3A--B](#fig2s3){ref-type="fig"}, see Materials and methods).

Surprisingly, we also observed sizeable populations of RNAs exhibiting noncanonical nuclear--cytoplasmic partitioning. 3161 mRNAs---including *C1orf63*, for example ([Figure 2D](#fig2){ref-type="fig"}, *top right*)---appeared preferentially nuclear. Many of these species have been proposed to play a role in dampening gene expression noise ([@bib4]). Conversely, 81 lncRNAs appeared preferentially cytoplasmic ([Figure 2D](#fig2){ref-type="fig"}, *bottom left*); these include the known cytoplasmic lncRNA *SNHG5*, a modulator of staufen-mediated decay that influences colorectal tumor growth ([@bib16]; [@bib15]) ([Figure 2D](#fig2){ref-type="fig"}, *bottom right*). We were concerned that this atypical RNA localization might be artifactual, since diffusion of proteins between subcellular compartments during a ten-minute formaldehyde treatment might allow aberrant RNA-protein interactions to be chemically crosslinked. To rule out this possibility, we monitored the localization of APEX-labeled species during the course of a BP-first/crosslink-second NLS-APEX2-RIP experiment, and failed to observe significant migration of biotinylated proteins from the nucleus into the cytosol ([Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}).

Our APEX-RIP nuclear and cytosolic RNA lists provide an opportunity for a head-to-head comparison with the traditional Fractionation-Seq method for mapping subcellular RNA localization. ROC analysis of HEK 293T fractionation-Seq data obtained using library synthesis and sequencing protocols very similar to our own (see Materials and methods, [@bib67]) yielded 5363 nuclear RNAs and 5011 cytosolic RNAs enriched by fractionation ([Figure 2---figure supplement 3D--G](#fig2s3){ref-type="fig"}; [Supplementary file 2D-F](#supp2){ref-type="supplementary-material"}). Of these RNAs, 63% (3358) were also enriched in our APEX-RIP nuclear dataset, implying general agreement between the two technologies ([Figure 2E](#fig2){ref-type="fig"}). Notably, APEX-RIP also enriched nearly 2400 additional transcripts. These may be nuclear-localized RNAs that were opaque to the fractionation protocol, or contaminants enriched by APEX-RIP. To address this latter possibility, we examined each dataset for conspicuous non-nuclear contaminants: RNAs that are known to be localized at the Endoplasmic Reticulum ([@bib31]). Satisfyingly, each nuclear dataset exhibited similarly low levels of ER contaminants (1.6% and 1.3%, respectively, [Figure 2F](#fig2){ref-type="fig"}, *left*).

To compare the coverage, or sensitivity, of each method (sometimes termed recall), we examined the enrichment in each dataset of lncRNAs, which are thought to be predominantly nuclear ([@bib16]). We assembled a list of 827 annotated lncRNAs (GENCODE v19) with average pre-enrichment FPKM greater than 1.0 ([Supplementary file 2G](#supp2){ref-type="supplementary-material"}). Of these lncRNAs, 53.6% are enriched in our APEX-RIP-derived nuclear dataset, while nuclear Fractionation-Seq from the same cell line enriched only 42.2% ([Figure 2F](#fig2){ref-type="fig"}, *right*). We conclude that APEX-RIP rivals or outperforms Fractionation-Seq in terms of both specificity and coverage, for analysis of endogenous RNA subcellular localization.

Enrichment of RNAs proximal to the ER membrane {#s2-3}
----------------------------------------------

Having established that APEX-RIP can enrich RNAs in membrane-enclosed cellular compartments, we next sought to address whether the technique could successfully capture the transcriptomes of 'open' subcellular regions. Previous proteomic work has shown that APEX tagging exhibits sufficient spatial specificity for such open compartments, since this technology has produced highly specific proteomic maps of, for example, the mammalian neuronal synaptic cleft ([@bib42]), outer mitochondrial membrane ([@bib28]), mitochondrial nucleoid ([@bib24]), and G-protein coupled receptor interaction networks ([@bib41]; [@bib54]). We were unsure, however, if the additional formaldehyde crosslinking step would preserve or blur the estimated \<5 nanometer spatial resolution of APEX labeling.

As a test case for the generality of APEX-RIP at such open compartments, we selected the Endoplasmic Reticulum (ER). The ER is an appealing target for several reasons. First, it is host to a known set of characteristic RNAs that we can use as positive controls---the so-called 'secretome'---which comprises mRNAs encoding secreted, glycosylated, and/or transmembrane proteins that are translated on the rough ER. Second, the ER provides the opportunity to compare the efficacy of APEX-RIP to alternative approaches, since RNAs in this subcellular locale have been previously characterized both by Fractionation-Seq, and by a newer methodology termed proximity-dependent ribosome profiling ([@bib31]; [@bib72]). This latter technique maps active protein translation at the ER membrane by combining ribosome profiling ([@bib30]) with proximity-restricted sequence-specific biotinylation, using an ER-targeted biotin ligase and ribosomes that are tagged with the peptide substrate (AviTag) of that ligase. Although the library preparation protocols used in each of these studies varied significantly from our own (see Materials and methods), by focusing our analyses on the fold enrichment of transcripts between matched input and ER-bound samples---and not on absolute transcript abundances---we hoped to control for these differences.

Since it was initially unclear which face of the ER membrane (cytosolic or luminal) would be most amenable to the APEX-RIP method, we generated fusion constructs that localized the peroxidase catalytic center to each ([Figure 3A--B](#fig3){ref-type="fig"}, [Supplementary file 5A](#supp5){ref-type="supplementary-material"}). ERM-APEX2 targets APEX2 to the ER cytosolic surface via a 27-amino acid fragment derived from the native ER membrane (ERM) protein cytochrome P450 C1. HRP-KDEL targets horseradish peroxidase (HRP) to the ER lumen via an N-terminal ER-targeting signal and a C-terminal KDEL ER-retention motif ([@bib46]). We have shown that HRP catalyzes the same proximity-dependent biotinylation chemistry as APEX2 ([@bib42]), but has higher specific activity than APEX2 in the ER lumen ([@bib37]). We generated HEK 293T cells stably expressing ERM-APEX2 and HRP-KDEL, and confirmed by microscopy and streptavidin blotting that each produced the expected labeling patterns ([Figure 3C and D](#fig3){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [Supplementary file 5B](#supp5){ref-type="supplementary-material"}. *see also* [@bib28]), [Figure 1D](#fig1){ref-type="fig"}). Next, we compared the efficacy of each construct for target RNA isolation, using the biotinylation-first/crosslinking-second APEX-RIP protocol, and analyzing our results via qRT-PCR analysis of established secretome and non-secretome mRNAs ([@bib31]). Parallel experiments with APEX2-NES cells served as negative controls ([Figure 3E](#fig3){ref-type="fig"}, [Supplementary file 5C](#supp5){ref-type="supplementary-material"}).

![APEX-RIP at the Endoplasmic Reticulum membrane.\
(**A**---**B**) Schematics summarizing alternating ER-targeting strategies. (**A**) HRP, targeted to the ER lumen with a KDEL sequence, biotinylates proteins within the ER. Red B: biotin. Red X's: chemical crosslinks induced by 0.1% formaldehyde treatment. Note that RNAs enriched by this approach may reside at the cytosolic face of the ER, or at the nuclear lamina, as shown. (**B**) APEX2, targeted to the ER membrane (ERM) by fusing it to the transmembrane segment of rabbit P450 C1, biotinylates proteins proximal to the cytosolic face of the ER. (**C**) Imaging of biotinylation from HRP-KDEL and ERM-APEX2 catalyzed reactions. HEK293T cells stably expressing HRP-KDEL or ERM-APEX2 were labeled with BP, fixed and imaged as in [Figure 1B](#fig1){ref-type="fig"}. Scale bars, 10 μm. Anti-RCN2 was used to mark ER lumen. (**D**) Streptavidin blot detection of resident ER proteins biotinylated by HRP-KDEL, as in [Figure 1C](#fig1){ref-type="fig"}. Arrowheads denote endogenously biotinylated proteins ([@bib8]). (**E**) qRT-PCR analysis, comparing the specificities of the labeling schemes shown in (**A--B**). Target and off-target genes were selected using previously-reported RNA abundances at the ER membrane ([@bib31]). Cytosolic APEX2 (APEX2--NES, as in [Figure 2](#fig2){ref-type="fig"}) serves as a negative control. Data are the mean of four replicates ± one standard deviation. Significance testing: Student's two-tailed t-test.](elife-29224-fig3){#fig3}

Intriguingly, while APEX-RIP from HRP-KDEL cells efficiently enriched target secretome mRNAs relative to non-target controls (average fold enrichment = 19.5, two-tailed t-test *p*-value = 0.00009), parallel experiments in ERM-APEX2 cells exhibited only modest, qualitative enrichment of target species (average fold enrichment = 1.49, two-tailed t-test *p*-value = 0.0515). Indeed, results from ERM-APEX2 cells were nearly indistinguishable from those acquired from APEX2-NES control cells (Student's two-tailed t-test comparing the two constructs *p*-value = 0.830, [Figure 3E](#fig3){ref-type="fig"}, *right*). This is surprising since proteomic experiments in HEK 293T cells expressing the identical ERM-APEX2 construct yielded highly specific enrichment of ER-localized proteins ([@bib28]).

Our data strongly imply that APEX-RIP does not have the same spatial specificity as peroxidase-catalyzed proteomic labeling, and may be limited by perturbations induced by formaldehyde crosslinking. However, we were highly encouraged by the data obtained with the HRP-KDEL construct, which we ascribe to the lower diffusion rates of both proteins and biotin-phenoxyl radicals when constrained within the limits of the ER lumen. We thus hypothesize that APEX-RIP with this construct is effective because formaldehyde crosslinking physically couples RNAs on the cytosolic face of the ER to protein complexes that are biotinylated within the ER lumen, thereby allowing target RNAs to be enriched by streptavidin ([Figure 3A](#fig3){ref-type="fig"}). Furthermore, we observed that the target specificity of this approach could be greatly improved by addition of a one-minute radical-quenching step in between the biotinylation and crosslinking steps in our protocol ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We surmise that this additional step prevents residual peroxidase-generated radicals from leaking into adjoining compartments when the integrity of the ER membrane is compromised during formaldehyde treatment.

Using this improved protocol, we performed APEX-RIP on HRP-KDEL cells ([Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}, [Supplementary file 3B](#supp3){ref-type="supplementary-material"}). Gene-level analysis, comparing RNA counts before and after streptavidin pulldown, revealed that the majority (72%) of secretome mRNAs expressed in our cells (defined by ER-proximal RNAs ([@bib31]) and Phobius-predicted mRNAs with exclusion of nuclear-encoded mitochondrial mRNAs, see Materials and methods) were enriched, while mRNAs in a test set of known non-secreted genes were not enriched, thus demonstrating the ability of our method to isolate ER-associated transcripts from the larger population of cellular RNAs ([Figure 4A](#fig4){ref-type="fig"}). Using *p*-values and ROC analysis, we determined the optimal log~2~ fold change significance threshold ([Figure 3---figure supplement 1D--F](#fig3s1){ref-type="fig"}; see Materials and methods), obtaining a final list of 2672 ER-associated RNAs that were significantly enriched in multiple experiments ([Figure 4B](#fig4){ref-type="fig"}; [Supplementary file 3A](#supp3){ref-type="supplementary-material"}). We did not detect any obvious trend among the 28% of expressed secretome mRNAs that were not represented in this list. However, this dataset exhibited 96.5% specificity, based on previous secretory annotation as defined by GOCC, SignalP, TMHMM, or Phobius ([@bib3]; [@bib57]; [@bib35]; [@bib36]), while mRNAs lacking such signals were concomitantly depleted ([Figure 4C](#fig4){ref-type="fig"}). Coverage was likewise exceptional (97%), as gauged by the successful recall of 71 mRNAs encoding well-established ER resident proteins ([Figure 4D](#fig4){ref-type="fig"}, [Supplementary file 3E](#supp3){ref-type="supplementary-material"}; see Materials and methods).

![Mapping the ER-proximal transcriptome with APEX--RIP.\
(**A**) Global analysis of RNA localization at the Endoplasmic Reticulum. Fold change = (FPKM~post-enrichment~/FPKM~pre-enrichment~). Horizontal dashed line indicates p-value = 0.05. Top histogram illustrates the distribution of RNAs with p-value = 5×10^−5^, which are boxed in gray in the scatter plot. Average data from two biological replicates are shown. Standard mRNAs encoding known secretory and non-secretory proteins are highlighted in red and blue, respectively (see Materials and methods). (**B**) Classification of APEX-RIP enriched, ER-associated RNAs. Collectively, all classes of non-coding RNAs constitute 6.7% of enriched genes (178 of 2672 RNAs). (**C**) Specificity analysis for protein-coding mRNAs in the APEX-RIP-derived ER-associated RNA list. The total number of RNA species in each condition is indicated above each column. 96.5% of the 2494 APEX-RIP ER-enriched mRNAs exhibit some form of secretory annotation (as predicted by Phobius, TMHMM, SignalP, or GOCC, *see methods*), whereas only 53.8% of total mRNAs expressed in HEK293T cells (FPKM ≥ 1.0) are similarly classified (*left*). (**D**) Target recall of ER APEX-RIP exceeds those of proximity-restricted ribosome profiling ([@bib31]: see [Supplementary file 3D](#supp3){ref-type="supplementary-material"}) and biochemical fractionation ([@bib60]; see [Supplementary file 3C](#supp3){ref-type="supplementary-material"}). See also: [Supplementary file 3E](#supp3){ref-type="supplementary-material"}. (**E**) Venn diagram comparing RNA datasets. Note that all enriched RNAs in Reid et al. ER fractionation-Seq dataset were mRNAs. See also: [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[2](#fig3s2){ref-type="fig"}.](elife-29224-fig4){#fig4}

We next compared the KDEL-APEX-RIP ER-associated RNA dataset to analogous results obtained by subcellular biochemical fractionation ([@bib60]), and by proximity-dependent ribosome profiling ([@bib31]) ([Supplementary file 3C-D](#supp3){ref-type="supplementary-material"}, respectively). Encouragingly, KDEL-APEX-RIP captures the majority of RNAs enriched by each of these alternative techniques (69% and 97%, respectively, [Figure 4E](#fig4){ref-type="fig"}), implying broad agreement between the different methodologies. To examine this further, we quantified the specificity and coverage of each approach, as above (see Materials and methods). Specificity analysis demonstrated that APEX-RIP and ribosome profiling exhibited similarly high specificity (96.5% and 99.2%, respectively). However, Fractionation-Seq was substantially noisier, such that only 91% of enriched mRNAs bore a secretory annotation ([Figure 4C](#fig4){ref-type="fig"}); the remaining 9% comprised sizeable populations of conspicuous contaminants ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). The coverage of ER-localized mRNAs retrieved by APEX-RIP (97%) was also considerably higher than those retrieved by both Fractionation-Seq and ribosome profiling (73% and 70%, respectively, [Figure 4D](#fig4){ref-type="fig"}). We attribute the enhanced coverage of APEX-RIP to its higher sensitivity, since this method appears better suited for capturing RNAs with lower abundances than the alternative approaches. Of the transcripts enriched by Frac-Seq or ribosome profiling, 95% have input abundances of 3.68 and 6.49 FPKM or higher, respectively, whereas those enriched by APEX-RIP have an analogous lower expression limit of 0.42 FPKM ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Such higher sensitivity may also explain why the set of RNAs enriched by APEX-RIP is so much larger than those obtained by fractionation and ribosome-profiling ([Figure 4E](#fig4){ref-type="fig"}). Excitingly, this further underscores the ability of APEX-RIP to recover RNAs that are opaque to other methods. While the vast majority (93.3%) of our enriched RNAs are mRNAs, we also enrich dozens of noncoding RNA species---including antisense RNAs and lincRNAs ([Figure 4B](#fig4){ref-type="fig"}). These RNAs are not translated, and thus cannot be detected by ribosome profiling, and tend to be lowly expressed, making them difficult targets for either ribosome profiling or Fractionation-Seq ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). While some proportion of these hits may constitute experimental noise, we believe the remainder hint at unanticipated roles for noncoding RNAs at the ER.

In summary, APEX-RIP is a powerful method for mapping endogenous RNAs proximal to the ER membrane, with a sensitivity and precision that equals or surpasses alternate technologies. We anticipate that this approach may be extensible to other membrane-abutting subcellular regions as well.

Hypotheses from ER and nuclear APEX-RIP datasets {#s2-4}
------------------------------------------------

We wondered if the RNA subcellular localization datasets produced by APEX-RIP could be mined for new biological hypotheses. To explore this possibility, we sought to computationally identify potential candidate RNAs that are localized at the interfaces between cellular compartments, since such transcripts are difficult to isolate by conventional approaches. We focused on two such interfaces: the ER-mitochondrial junction and the nuclear lamina.

We sought to identify RNAs localized to the ER-mitochondrial junction through close inspection of our KDEL dataset. It is thought that that the bulk of the nuclear-encoded mitochondrial proteome is translated either within the cytosol, or in proximity to mitochondria themselves ([@bib40]). However, of the 2494 mRNAs in our ER-associated RNA dataset, 135 code for mitochondrial proteins, as defined by GOCC. Since the majority of these genes (132 mRNAs, 98%) also carry secretory annotation, we considered the possibility that the translation or processing of these 135 mRNAs require machinery localized at the ER membrane. For example, these mRNAs might be translated at mitochondria-ER contact sites, some of which have been observed to contain ribosomes ([@bib14]). To gain initial insight into these unusual RNAs, we analyzed these genes to see whether, relative to total pool of mRNAs encoding mitochondrially-localized proteins, they were enriched in particular characteristics ([Supplementary file 4A](#supp4){ref-type="supplementary-material"}). Intriguingly, 62.7% of these mRNAs code for transmembrane proteins (as predicted by TMHMM), compared to only 20.4% of all nuclear-encoded mitochondrial genes ([Figure 5A](#fig5){ref-type="fig"}). Subcompartment analysis of this ER-proximal population was also revealing: of the 39 genes for which compartment-specific annotations were available, 49% (19 genes) encode proteins destined for the outer mitochondrial membrane (OMM), whereas OMM proteins comprise only 18% of the bulk mitochondrial proteome ([Figure 5B](#fig5){ref-type="fig"}). This may indicate something unique about the biogenesis of OMM proteins, since the mRNAs encoding IMM-destined proteins did not exhibit such enrichment (comprising \~41--44% of both our ER-proximal population, and the general mitochondrial proteome), and those encoding matrix and intermembrane space proteins were depleted in our set ([Figure 5B](#fig5){ref-type="fig"}). Interestingly, in yeast, proximity-dependent ribosome profiling near the OMM showed similar enrichment of mRNAs encoding proteins destined for the inner mitochondrial membrane ([@bib72]). Perhaps a subset of proteins destined for both the outer and inner mitochondrial membranes are locally translated at mitochondria-ER contact sites.

![APEX-RIP reveals RNAs with potentially novel localization.\
(**A**) Many mitochondrial transmembrane proteins appear to be translated at the ER. mRNAs encoding mitochondrial proteins (defined by GOCC and MitoCarta 1.0 ([@bib3]; [@bib55]) with predicted transmembrane helices (predicted by TMHMM ([@bib35]); red distribution) are preferentially enriched by HRP-KDEL APEX-RIP, relative to those encoding mitochondrial proteins lacking transmembrane domains (gray distribution). See [Supplementary file 3A](#supp3){ref-type="supplementary-material"}. (**B**) Mitochondrial proteins encoded by ER-proximal mRNAs are enriched for outer mitochondrial membrane (OMM) destined proteins, and de-enriched for matrix and intermembrane space (IMS) destined proteins. Predicted sub-mitochondrial localization of all GOCC-annotated mitochondrial proteins (*left*), those with mRNAs enriched by APEX2--NES (*middle*), and those enriched by HRP--KDEL (*right*). IMM: Inner mitochondrial membrane. The total number of mRNA species with annotated mitochondrial sublocalization is indicated above each column. See [Supplementary file 4A](#supp4){ref-type="supplementary-material"}. (**C**) Scheme for identifying putative RNAs associated with the nuclear lamina. Since subsets of laminar proteins should be biotinylated both by APEX2-NLS (*top right*) and by HRP-KDEL (*bottom right* and [Figure 3A](#fig3){ref-type="fig"}), we can intersect these two datasets to obtain a candidate list of nuclear lamina-localized RNAs. Notation as in [Figure 3A](#fig3){ref-type="fig"}. (**D**) Venn diagram identifying putative lamina-associated RNAs, defined as the overlap between HRP-KDEL- and APEX2-NLS-enriched RNAs. See also: [Supplementary file 4B](#supp4){ref-type="supplementary-material"}. Significance testing: hypergeometric test.](elife-29224-fig5){#fig5}

We adopted a slightly different computational approach to identify candidate nuclear laminar RNAs---transcripts that have long been proposed to contribute to the laminar functions of gene repression ([@bib34]) and nuclear architecture ([@bib9]), but for which few examples have been identified. Because intermembrane space of the nuclear envelope is contiguous with the ER lumen, we hypothesized that our KDEL-APEX-RIP experiment---in addition to enriching RNAs proximal to the ER---might also enrich RNAs at the nuclear lamina ([Figure 3A](#fig3){ref-type="fig"}). We therefore sought to discover candidate laminar RNAs by examining the population of KDEL-enriched RNAs for transcripts that are predominantly nuclear---that is, by intersecting our ER-associated and nuclear RNA lists ([Figure 5C](#fig5){ref-type="fig"}). When we performed this analysis, and filtered this intersected list to remove mRNAs that encode secretory proteins (for which our quantification may convolve nuclear-retained pre-mRNAs and mature ER-localized transcripts), we observed 104 candidate laminar RNAs, including 48 mRNAs and 56 noncoding RNA species ([Figure 5D](#fig5){ref-type="fig"}; [Supplementary file 4B](#supp4){ref-type="supplementary-material"}). Although some portion of this highly speculative list may comprise experimental noise, the target RNAs identified here represent a compelling starting point for exploration of regulatory RNAs that have long remained elusive. Furthermore, given the flexibility with which APEX-RIP can be applied in different subcellular compartments, we anticipate that this form of analysis could be widely used to generate novel hypotheses regarding RNA subcellular localization in a diverse range of cellular contexts.

Discussion {#s3}
==========

Methods for mapping RNA subcellular localization are constrained by the limits of their spatiotemporal precision, the diversity of RNA species that they can simultaneously analyze, their generality across cell types and compartments, and their ease of use. We believe that APEX-RIP holds substantial advantages to existing imaging- and sequencing-based techniques with regard to many of these factors.

Compared to imaging-based technologies, APEX-RIP offers superior target throughput, ease of use, and less cellular perturbation. For example, although modern variants of FISH can achieve extremely high spatial precision---even enabling the visualization of individual RNA molecules ([@bib5]) this technique requires the synthesis and testing of customized fluorescent probes for each transcript of interest, a cumbersome process that limits throughput ([@bib7]). A highly multiplexed FISH variant, MERFISH, substantially boosts throughput---enabling thousands of transcripts to be simultaneously visualized---but requires complex protocols for probe set design and imaging ([@bib10]). An alternate approach, FISSEQ, achieves similar target depth without the need for gene-specific probes, but instead relies on customized instrumentation and a rococo process of in situ sequencing and imaging ([@bib38]). Notably, without incorporating additional stains or markers, these imaging-based approaches provide little information regarding the local environment (i.e., proximal cellular compartments or features) near each RNA target. Furthermore, these techniques are perturbative in that they require extensively fixing and permeabilizing cells prior to data collection (up to several hours in 1--4% formaldehyde) which can destroy membranes and alter endogenous RNA localization ([@bib21]). This latter issue can be circumvented through a variety of live-cell imaging techniques, but these require the implementation of customized reagents that limit throughput, and may even distort the localization of the RNA targets under enquiry ([@bib56]; [@bib26]; [@bib53]). By contrast, APEX-RIP is unencumbered by many of these constraints. It does not require the development of target-specific expression constructs or probes; nor does it rely on specialized instrumentation. The protocol captures RNA localization in living cells without detergent or methanol treatment so that membranes and spatial relationships are preserved. The ensemble of RNA targets analyzed (and, for that matter, the array of RNA classes analyzed) is theoretically limited only by the library synthesis and sequencing protocols employed. Moreover, since APEX-RIP captures only RNAs proximal to or within a specific subcellular compartment, it offers greater information content than do its imaging-based alternatives.

Compared to fractionation-based technologies, APEX-RIP offers superior accuracy, ease of use, and general versatility. As illustrated in the nucleus and ER, our technique rivals or outperforms conventional Fractionation-Seq with regard to both target specificity and recall, apparently circumventing the dual issues of target loss and off-target contamination that can plague such approaches ([Figures 2E--F; 4C--E](#fig2){ref-type="fig"}). We ascribe this performance boost to two principal factors. First, the high spatiotemporal precision afforded by in situ biotinylation ([@bib61]) allows us to efficiently isolate target material from contaminants that might be difficult to remove by classical fractionation, thereby improving specificity. Second, covalently coupling target RNAs to affinity-tagged proteins allows us to recover low-abundance or weakly affiliated transcripts that might otherwise be lost during biochemical enrichment, thereby improving target recall ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Perhaps more importantly, however, we have achieved these results in a variety of subcellular compartments using a common protocol, thus obviating the need to develop customized purification schemes for each compartment. This generality should enable APEX-RIP to access 'unpurifiable' subcellular compartments for which such purification schemes would be impossible. While a related technology, proximity-dependent ribosome profiling, exhibits similar versatility within diverse subcellular milieus ([@bib31]), this approach is limited to actively translated mRNAs. It also requires biotin starvation prior to tagging, which is toxic to mammalian cells, and as such, prevents widespread application. As we have demonstrated, APEX-RIP can map diverse classes of noncoding RNA and quiescent mRNA ([Figure 4B](#fig4){ref-type="fig"}), and eschews toxic protocols that starve cells of essential nutrients for prolonged periods of time.

The APEX-RIP methodology does have notable limitations. Cells to be analyzed must express a recombinant construct, in contrast to FISH and Fractionation-Seq, which can be performed on genetically unmodified cells, or on intact tissues. Application of APEX-RIP in developing animals, or in situ within animal nervous systems---cases where RNA localization is known to play a crucial regulatory role---would require the generation of a transgenic organism, and may be hindered by the need to deliver BP, H~2~O~2,~ and formaldehyde into intact tissue. APEX-RIP also appears to exhibit poorer spatial specificity in membrane-free subcellular regions, since targeting APEX2 to cytoplasmic face of the endoplasmic reticulum failed to enrich secretome mRNAs from cytosolically-localized transcripts ([Figure 3E](#fig3){ref-type="fig"}). However, since the ER membrane forms a convoluted network that occupies a substantial volume of the cytosol, it is unclear the degree to which this apparent lack of specificity might apply to other, more discrete subcellular milieus.

The APEX peroxidase used here has also previously been used to generate contrast for electron microscopy in fixed cells ([@bib46]; [@bib37]), and for spatially-resolved proteomic mapping in living cells ([@bib61]; [@bib29]; [@bib42]; [@bib24]; [@bib28]; [@bib49]). This study extends APEX to a new class of applications and to a new biopolymer. In principle, it should be possible to use a single APEX-expressing cell line to characterize a target subcellular compartment by electron microscopic, proteomic, and transcriptomic means. Related methods for proteomic mapping, such as BioID ([@bib64]), lack this versatility, because the underlying chemistry is not as flexible as the one-electron oxidation reaction catalyzed by APEX.

We anticipate that the initial subcellular transcriptomic map presented in this work---probing the mitochondrial matrix, cytosol, nucleus, and ER membrane of HEK 293T cells---will serve as a valuable resource for cell biologists. Analysis of these data has already yielded potential insight into nuclear-retained mRNAs, cytosolic lncRNAs, putative lamina-localized RNAs, and genes that may be translated locally at mitochondria-endoplasmic reticulum junctions. Applying APEX-RIP to other subcellular compartments will further expand the depth and breadth of this map. Furthermore, given the high temporal resolution of APEX-RIP, we imagine that our technology might enable profiling of subcellular RNA pools in response to acute stimuli or drugs, or throughout stages of the cell cycle and development.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\        Designation                                  Source or reference             Identifiers                                                                  Additional information
  or resource                                                                                                                                                                              
  ------------------------------ -------------------------------------------- ------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  cell line (human)              HEK293T                                      ATCC                            CRL3216; RRID: [CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)         

  cell line (human)              mito-APEX2 (HEK293T)                         this paper                                                                                                   mito-BamHI-V5-APEX2\
                                                                                                                                                                                           CMV promoter\
                                                                                                                                                                                           Mito is a 24-amino acidmitochondrial targeting sequence (MTS) derived from COX4. V5: GKPIPNPLLGLDST

  cell line (human)              APEX2-NLS (HEK293T)                          this paper                                                                                                   NotI-V5-APEX2-EcoRI-3xNLS-NheI\
                                                                                                                                                                                           CMV promoter\
                                                                                                                                                                                           NLS: DPKKKRKV

  cell line (human)              APEX2-NES (HEK293T)                          PMID: 28441135                                                                                               BstBI-FLAG-APEX2-NES-NheI\
                                                                                                                                                                                           CMV promoter\
                                                                                                                                                                                           NES: LQLPPLERLTLD

  cell line (human)              ERM-APEX2 (HEK293T)                          PMID: 28441135                                                                                               BstBI-ERM-APEX2-V5-NheI\
                                                                                                                                                                                           CMV promoter\
                                                                                                                                                                                           ERM is ER membrane targeting sequence derived from N-terminal 27 amino acids of rabbit P450 C1 (MDPVVVLGLCLSCLLLLSLWKQSYGGG)

  cell line (human)              HRP-KDEL (HEK293T)                           this paper                                                                                                   NotI-IgK-HRP-V5-KDEL-IRES-puromycin-XbaI\
                                                                                                                                                                                           CMV promoter\
                                                                                                                                                                                           IgK is N-terminal signaling sequence that brings protein to ER (METDTLLLWVLLLWVPGSTGD). KDEL is ER-retaining sequence

  antibody                       Anti V5                                      Life Technologies               R960-25; RRID: [AB_2556564](https://scicrunch.org/resolver/AB_2556564)       Dilution 1:1000

  antibody                       Anti FLAG                                    Agilent                         200472                                                                       Dilution 1:500

  antibody                       Anti TOM20                                   Santa Cruz Biotechnology        sc-11415; RRID: [AB_2207533](https://scicrunch.org/resolver/AB_2207533)      Dilution 1:400

  antibody                       Anti RCN2                                    Proteintech                     10193--2-AP; RRID: [AB_2180018](https://scicrunch.org/resolver/AB_2180018)   Dilution 1:200

  antibody                       Anti Mouse-AlexaFlour488                     Life Technologies               A-11029; RRID: [AB_2534088](https://scicrunch.org/resolver/AB_2534088)       Dilution 1:1000

  antibody                       Anti Mouse-AlexaFlour568                     Life Technologies               A-11031; RRID: [AB_144696](https://scicrunch.org/resolver/AB_144696)         Dilution 1:1000

  antibody                       Streptavidin-HRP                             ThermoFisher                    S-911                                                                        Dilution 1:1000

  recombinant DNA reagent        Mito-APEX\                                   PMID: 23371551                  pCDNA vector                                                                 
                                 (plasmid)                                                                                                                                                 

  recombinant DNA reagent        mito-APEX2 (plasmid)                         this paper                      pLX304 vector                                                                mito-BamHI-V5-APEX2\
                                                                                                                                                                                           CMV promoter\
                                                                                                                                                                                           Mito is a 24-amino acidmitochondrial targeting sequence (MTS) derived from COX4. V5: GKPIPNPLLGLDST

  recombinant DNA reagent        APEX2-NLS (plasmid)                          this paper                                                                                                   NotI-V5-APEX2-EcoRI-3xNLS-NheI\
                                                                                                                                                                                           CMV promoter\
                                                                                                                                                                                           NLS: DPKKKRKV

  recombinant DNA reagent        HRP-KDEL\                                    this paper                                                                                                   NotI-IgK-HRP-V5-KDEL-IRES-puromycin-XbaI\
                                 (plasmid)                                                                                                                                                 CMV promoter\
                                                                                                                                                                                           IgK is N-terminal signaling sequence that brings protein to ER (METDTLLLWVLLLWVPGSTGD). KDEL is ER-retaining sequence

  sequence-based reagent         Ribo-Zero Gold rRNA removal kit (Illumina)   Illiumina                       MRZG12324                                                                    

  sequence-based reagent         Truseq RNA sample preparation kit V2         Illiumina                       RS-122--2001                                                                 

  sequence-based reagent         MT-ND1 forward                               this paper                                                                                                   CACCTCTAGCCTAGCCGTTT

  sequence-based reagent         MT-ND1 reverse                               this paper                                                                                                   CCGATCAGGGCGTAGTTTGA

  sequence-based reagent         MT-ND2 forward                               this paper                                                                                                   CTTAAACTCCAGCACCACGAC

  sequence-based reagent         MT-ND2 reverse                               this paper                                                                                                   AGCTTGTTTCAGGTGCGAGA

  sequence-based reagent         MT-ND3 forward                               this paper                                                                                                   CCGCGTCCCTTTCTCCATAA

  sequence-based reagent         MT-ND3 reverse                               this paper                                                                                                   AGGGCTCATGGTAGGGGTAA

  sequence-based reagent         MT-ND4 forward                               this paper                                                                                                   ACAACACAATGGGGCTCACT

  sequence-based reagent         MT-ND4 reverse                               this paper                                                                                                   CCGGTAATGATGTCGGGGTT

  sequence-based reagent         MT-ND4L forward                              this paper                                                                                                   TCGCTCACACCTCATATCCTC

  sequence-based reagent         MT-ND4L reverse                              this paper                                                                                                   AGGCGGCAAAGACTAGTATGG

  sequence-based reagent         MT-ND5 forward                               this paper                                                                                                   TCCATTGTCGCATCCACCTT

  sequence-based reagent         MT-ND5 reverse                               this paper                                                                                                   GGTTGTTTGGGTTGTGGCTC

  sequence-based reagent         MT-ND6 forward                               this paper                                                                                                   GGGTTGAGGTCTTGGTGAGT

  sequence-based reagent         MT-ND6 reverse                               this paper                                                                                                   ACCAATCCTACCTCCATCGC

  sequence-based reagent         MT-CYTB forward                              this paper                                                                                                   TCTTGCACGAAACGGGATCA

  sequence-based reagent         MT-CYTB reverse                              this paper                                                                                                   CGAGGGCGTCTTTGATTGTG

  sequence-based reagent         MT-COX1 forward                              this paper                                                                                                   TCCTTATTCGAGCCGAGCTG

  sequence-based reagent         MT-COX1 reverse                              this paper                                                                                                   ACAAATGCATGGGCTGTGAC

  sequence-based reagent         MT-COX2 forward                              this paper                                                                                                   AACCAAACCACTTTCACCGC

  sequence-based reagent         MT-COX2 reverse                              this paper                                                                                                   CGATGGGCATGAAACTGTGG

  sequence-based reagent         MT-COX3 forward                              this paper                                                                                                   CTAATGACCTCCGGCCTAGC

  sequence-based reagent         MT-COX3 reverse                              this paper                                                                                                   AGGCCTAGTATGAGGAGCGT

  sequence-based reagent         MT-ATP6 forward                              this paper                                                                                                   TTCGCTTCATTCATTGCCCC

  sequence-based reagent         MT-ATP6 reverse                              this paper                                                                                                   GGGTGGTGATTAGTCGGTTGT

  sequence-based reagent         MT-ATP8 forward                              this paper                                                                                                   ACTACCACCTACCTCCCTCAC

  sequence-based reagent         MT-ATP8 reverse                              this paper                                                                                                   GGCAATGAATGAAGCGAACAGA

  sequence-based reagent         MT-RNR1 forward                              this paper                                                                                                   CATCCCCGTTCCAGTGAGTT

  sequence-based reagent         MT-RNR1 reverse                              this paper                                                                                                   TGGCTAGGCTAAGCGTTTTGA

  sequence-based reagent         MT-RNR2 forward                              this paper                                                                                                   CAGCCGCTATTAAAGGTTCGT

  sequence-based reagent         MT-RNR2 reverse                              this paper                                                                                                   AAGGCGCTTTGTGAAGTAGG

  sequence-based reagent         GAPDH forward                                this paper                                                                                                   TTCGACAGTCAGCCGCATCTTCTT

  sequence-based reagent         GAPDH reverse                                this paper                                                                                                   GCCCAATACGACCAAATCCGTTGA

  sequence-based reagent         XIST forward                                 this paper                                                                                                   CCCTACTAGCTCCTCGGACA

  sequence-based reagent         XIST reverse                                 this paper                                                                                                   ACACATGCAGCGTGGTATCT

  sequence-based reagent         EMC10 forward                                this paper                                                                                                   TTCATTGAGCGCCTGGAGAT

  sequence-based reagent         EMC10 reverse                                this paper                                                                                                   TTCATTGAGCGCCTGGAGAT

  sequence-based reagent         PCSK1N forward                               this paper                                                                                                   GAGACACCCGACGTGGAC

  sequence-based reagent         PCSK1N reverse                               this paper                                                                                                   AATCCGTCCCAGCAAGTACC

  sequence-based reagent         SSR2 forward                                 this paper                                                                                                   GTTTGGGATGCCAACGATGAG

  sequence-based reagent         SSR2 reverse                                 this paper                                                                                                   CTCCACGGCGTATCTGTTCA

  sequence-based reagent         TMX1 forward                                 this paper                                                                                                   ACGGACGAGAACTGGAGAGA

  sequence-based reagent         TMX1 reverse                                 this paper                                                                                                   ATTTTGACAAGCAGGGCACC

  sequence-based reagent         SFT2D2 forward                               this paper                                                                                                   CCATCTTCCTCATGGGACCAG

  sequence-based reagent         SFT2D2 reverse                               this paper                                                                                                   GCAGAACACAGGGTAAGTGC

  sequence-based reagent         EPT1 forward                                 this paper                                                                                                   TGGCTTTCTGCTGGTCGTAT

  sequence-based reagent         EPT1 reverse                                 this paper                                                                                                   AATCCAAACCCAGTCAGGCA

  sequence-based reagent         DRAP1 forward                                this paper                                                                                                   ACATCCCACCTGAAGCAGTG

  sequence-based reagent         DRAP1 reverse                                this paper                                                                                                   GATGCCACCAGGTCCTTCAA

  sequence-based reagent         FAU forward                                  this paper                                                                                                   TCCTAAGGTGGCCAAACAGG

  sequence-based reagent         FAU reverse                                  this paper                                                                                                   GTGGGCACAACGTTGACAAA

  sequence-based reagent         SUB1 forward                                 this paper                                                                                                   CGTCACTTCCGGTTCTCTGT

  sequence-based reagent         SUB1 reverse                                 this paper                                                                                                   TGATTTAGGCATCGCTTCGC

  sequence-based reagent         LSM6 forward                                 this paper                                                                                                   CGGACGACCAGTTGTGGTAA

  sequence-based reagent         LSM6 reverse                                 this paper                                                                                                   CCAGGACCCCTCGATAATCC

  sequence-based reagent         COPS2 forward                                this paper                                                                                                   AGGAGGACTACGACCTGGAAT

  sequence-based reagent         COPS2 reverse                                this paper                                                                                                   GCCGCTTTTGGGTCATCTTC

  sequence-based reagent         CGGBP1 forward                               this paper                                                                                                   GCCTCGTCCACTTTCCCTAA

  sequence-based reagent         CGGBP1 reverse                               this paper                                                                                                   TCATGCCTTTACGTAGGATCGAG

  sequence-based reagent         BCA53 forward                                this paper                                                                                                   TCTTGCCTGCTCCACAGTTT

  sequence-based reagent         BCA53 reverse                                this paper                                                                                                   CAAACACCAAGGAGGGGTCT

  sequence-based reagent         CEP128 forward                               this paper                                                                                                   TACAGTAATGGACAGGCGGG

  sequence-based reagent         CEP128 reverse                               this paper                                                                                                   TCCGGAGTTGGTCGATTGAT

  sequence-based reagent         MAD1L1 forward                               this paper                                                                                                   CGAGTCTGCCATCGTCCAA

  sequence-based reagent         MAD1L1 reverse                               this paper                                                                                                   GCACTCTCCACCTGCTTCTT

  sequence-based reagent         RAD51B forward                               this paper                                                                                                   TTTGGACGAAGCCCTGCAT

  sequence-based reagent         RAD51B reverse                               this paper                                                                                                   CACAACCTGGTGGACCTGTA

  sequence-based reagent         RBPMS forward                                this paper                                                                                                   ACAGTCGCTCAGAAGCAGAG

  sequence-based reagent         RBPMS reverse                                this paper                                                                                                   CGAAGCGGATGCCATTCAAA

  sequence-based reagent         TCF7 forward                                 this paper                                                                                                   TCAACAGCCCACATCCCAC

  sequence-based reagent         TCF7 reverse                                 this paper                                                                                                   AGAGGCCTGTGAACTTGCTT

  sequence-based reagent         HOOK2 forward                                this paper                                                                                                   TTTGCTGAAAAGGAAGCTGGA

  sequence-based reagent         HOOK2 reverse                                this paper                                                                                                   GCAACTCCAGATCTGCCTCA

  sequence-based reagent         MAN2C1 forward                               this paper                                                                                                   ATGAGGCCCACAAGTTCCTG

  sequence-based reagent         MAN2C1 reverse                               this paper                                                                                                   TCTCATAGGTGGCCTGGGAA

  peptide, recombinant protein                                                                                                                                                             

  commercial assay or kit                                                                                                                                                                  

  chemical compound, drug        Biotin-phenol (BP)                           PMID: 23371551                                                                                               

  software, algorithm            Tophat v2.1.1                                DOI: 10.1186/gb-2013-14-4-r36   RRID:[SCR_013035](https://scicrunch.org/resolver/SCR_013035)                 

  software, algorithm            CuffDiff2                                                                    RRID:[SCR_001647](https://scicrunch.org/resolver/SCR_001647)                 

  software, algorithm            Slidebook 6.0                                                                RRID:[SCR_014300](https://scicrunch.org/resolver/SCR_014300)                 

  software, algorithm            DAVID bioinformatics analysis                                                RRID:[SCR_003033](https://scicrunch.org/resolver/SCR_003033)                 

  other                                                                                                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmids and cloning {#s4-1}
--------------------

The pCDNA3 mito-APEX plasmid was published previously ([@bib61]). The Mito-APEX2 construct was cloned from this plasmid using a two-step protocol. First, the A134P mutation ([@bib37]) was introduced into the APEX gene itself, using QuikChange mutagenesis (Agilent Technologies, Santa Clara, CA), and thereafter the APEX2 gene was moved to the lentiviral vector pLX304, via Gateway cloning (ThermoFisher Scientific, Waltham, MA), to generate the plasmid pLX304 mito-APEX2. Other APEX-fusion constructs (pLX304 APEX2-NLS, pLX304 APEX2-NES, and pLX304 ERM-APEX2) were cloned by Gibson assembly (New England Biolabs, Ipswich, MA), using PCR to add targeting sequences and Gibson Assembly homology arms to the APEX2 gene, and joining the resulting insert into the pLX304 vector digested by *BstBI* and *NheI*. To clone HRP-KDEL, the HRP-KDEL-IRES-Puromycin cassette from HRP C ([@bib47]), was PCR-amplified and cloned into pCDNA3 using *NotI* and *XbaI* sites. Targeting sequences and restriction sites for all constructs are listed in ([Supplementary file 5A](#supp5){ref-type="supplementary-material"}).

Mammalian cell culture {#s4-2}
----------------------

Human embryonic kidney (HEK) 293 T cells (RRID: [CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)) were obtained, authenticated by STR profiling from ATCC, and cultured in growth media consisting of 1:1 DMEM:MEM (Cellgro, ThermoFisher Scientific, Manassas, VA), supplemented with 10% Fetal Bovine Serum (FBS), 50 units/mL penicillin, and 50 μg/mL streptomycin, at 37°C and under 5% CO~2~. Cells were discarded at 25 passages. Cell lines were not tested for Mycoplasma contamination. For fluorescence microscopy imaging experiments ([Figures 1B](#fig1){ref-type="fig"}, [2A](#fig2){ref-type="fig"} and [3C](#fig3){ref-type="fig"}, and [Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}), cells were grown on 7 × 7 mm glass coverslips in 48-well plates. To improve cell adherence, coverslips were pretreated with 50 μg/mL fibronectin (Millipore, Burlington, MA) for 20 min at 37°C and washed once with Dulbecco's phosphate-buffered saline (DPBS), pH 7.4. Cells used for generating lentivirus were grown on T25 plates, in MEM supplemented as above, at 37 °C under 5% CO~2~.

Preparation of cell lines stably expressing APEX-fusion constructs {#s4-3}
------------------------------------------------------------------

To prepare lentivirus, one \~ 70% confluent T25 plate of HEK 293T cells, grown as above, was co-transfected with 2.5 μg of APEX2 fusion plasmid, along with 0.25 μg and 2.25 μg, respectively, of the lentivirus packaging plasmids VSV-G, and dR8.91 ([@bib55]). Transfection mixes used 10 μL Lipofectamine 2000 (ThermoFisher Scientific) and were brought to a final volume of 2 mL with unsupplemented MEM. The cells were transfected for 3 hr, after which media was replaced with 2 ml of fresh growth media with FBS. After 48 hr, the lentiviral supernatant was collected by aspiration and filtered through a 0.45 μm syringe-mounted filter. This filtered supernatant was immediately used to infect cells. HEK293T cells, grown in 6-well plates as described above, were infected at \~50% confluency, grown for 2 days, followed by selection in growth medium supplemented with 8 μg/mL blasticidin for 7 days, before further analysis.

For the cells stably expressing HRP-KDEL, HEK293T cells at \~60% confluency, grown in 6-well plates as described above, were transfected with the mixture of 150 μg of plasmid and 10 μL Lipofectamine 2000 in unsupplemented MEM for 3 hr, after which media was replaced with 2 ml of fresh growth media with FBS. After 48 hr, the cells were trypsinized and replated in T25 flask in growth medium supplemented with 1 μg/mL puromycin for 7 days, before further analysis.

Immunofluorescence staining and microscopy {#s4-4}
------------------------------------------

For immunofluorescence experiments ([Figures 1B](#fig1){ref-type="fig"}, [2A](#fig2){ref-type="fig"} and [3C](#fig3){ref-type="fig"}, and [Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}), stable APEX- or HRP-expressing cells were BP-labeled and crosslinked, as described below, and subsequently fixed with 4% (v/v) paraformaldehyde in PBS at room temperature for 10 min. Cells were then washed with PBS three times and permeabilized with cold methanol at --20°C for 5 min. Cells were washed again three times with room-temperature PBS and then incubated with primary antibodies in PBS--supplemented with 1% (w/v) Bovine Serum Albumin (BSA)--for 1 hr at room temperature. After washing three times with PBS, cells were incubated with secondary antibodies and neutravidin-AlexaFluor647 (1:1000 dilution) in BSA-supplemented PBS for 30 min. Cells were then washed three times with PBS and imaged by confocal fluorescence microscopy, or in PBS at 4°C in light-tight containers prior to imaging. Primary and secondary antibodies used were listed in [Supplementary file 5B](#supp5){ref-type="supplementary-material"}.

Fluorescence confocal microscopy was performed with a Zeiss AxioObserver microscope with 63 × oil immersion objectives, outfitted with a Yokogawa spinning disk confocal head, a Cascade II:512 camera, a Quad-band notch dichroic mirror (405/488/568/647), 405 (diode), 491 (DPSS), 561 (DPSS) and 640 nm (diode) lasers (all 50 mW). Alexa Fluor488 (491 laser excitation, 528/38 emission), Alexa Fluor 568 (561 laser excitation, 617/73 emission), and AlexaFluor647 (640 laser excitation, 700/75 emission) and differential interference contrast (DIC) images were acquired through a 63x oil-immersion lens. Acquisition times ranged from 100 to 1,000 ms. For image acquisition and analysis, we used the SlideBook 6.0 software (Intelligent Imaging Innovations, Denver, CO, RRID:[SCR_014300](https://scicrunch.org/resolver/SCR_014300)).

Unless otherwise noted, imaging data are representative of three independent experiments with ≥5 fields of view each.

Immunofluorescence measuring biotinylated protein diffusion {#s4-5}
-----------------------------------------------------------

HEK 293 T cells stably expressing APEX2-NLS were seeded onto fibronectin-coated coverslips and grown in 48-well plates, in 200 μL of 1:1 MEM:DMEM, supplemented with 15% (v/v) FBS, per well. At \~60% confluency, cells were transfected with a GFP expression plasmid (pCMV-EGFP, addgene plasmid 3525) using polyethyleneimine (PEI). Briefly, 150 ng plasmid was diluted into a 1:1 MEM:DMEM solution and incubated with 1 uL of PEI in a final reaction volume of 20 μL, for 15 min at room temperature, and added dropwise to cells. After 16 hr, cells were labeled and crosslinked according to BP--quench--then--crosslinking protocol (*see below*). At the indicated time points ([Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}), cell growth media was aspirated, and cells were fixed with 4% (v/v) formaldehyde in PBS supplemented, with 5 mM Trolox, 10 mM Ascorbate, 10 mM sodium azide, for 10 min at room temperature. Cells were washed twice with PBS, permeablized with methanol at −20°C for 5 min, and immunostained as described above. To stain the nucleus and biotinylated species, 0.1 ug/mL DAPI (4', 6-Diamidino-2-Phenylindole) and neutravidin-AlexaFluor647 (1:1000 dilution) were supplemented during the secondary antibody incubation. All primary and secondary antibodies used are listed in [Supplementary file 5B](#supp5){ref-type="supplementary-material"}. The data in [Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"} are representative of the experiments with ≥15 fields of view each.

The nuclear and cytosolic biotinylation ratio ([Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}) was quantified using Slidebook 6.0. Nuclear biotinylation was quantified as the signal within the DAPI-stained area; cytosolic biotinylation was quantified as the signal within the GFP-labeled area, excluding that within DAPI-stained area.

Western and streptavidin blotting {#s4-6}
---------------------------------

For blotting experiments ([Figures 1C](#fig1){ref-type="fig"} and [3D](#fig3){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), stable APEX- or HRP-expressing cells were grown in 6-well plates, as described above. After APEX labeling (*see below*), the cells were harvested by scraping, pelleted by centrifugation at 3,000 × *g* for 10 min, and stored at --80°C prior to use. Thawed pellets were lysed by gentle pipetting in RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 5 mM EDTA), supplemented with 1 × protease cocktail (Sigma Aldrich, St Louis, MO), 1 mM PMSF (phenylmethylsulfonyl fluoride), for 5 min at 4°C. Lysates were then clarified by centrifugation at 15,000 × *g* for 10 min at 4°C before separation on homemade 8% SDS-PAGE gels. Gels were transferred to nitrocellulose membranes, stained by Ponceau S (0.1% (w/v) Ponceau S, 5% (v/v) acetic acid, in water) for 10 min at room temperature, and imaged. The blots were then blocked with blocking buffer (3% (w/v) BSA, 0.1% (v/v) Tween-20 in Tris-buffered saline) for 1 hr at room temperature, and incubated with primary antibodies in blocking buffer for 1 hr more. The dilutions of the antibodies are as followed: Mouse anti-V5 antibody (ThermoFisher Scientific RRID: [AB_2556564](https://scicrunch.org/resolver/AB_2556564)) 1:1000 dilution and Mouse anti-FLAG antibody (ThermoFisher Scientific) 1:800 dilution. Blots were rinsed four times for 5 min with wash buffer (0.1% Tween-20 in Tris-buffered saline), and then immersed in blocking buffer supplemented with Goat anti-Mouse IgG H + L HRP Conjugate (1:3000 dilution, Bio-Rad Laboratories, Hercules, CA), for 1 hr at room temperature. Blots were rinsed four times for 5 min with wash buffer, and developed with the Clarity reagent (Bio-Rad Laboratories) and imaged on an Alpha Innotech gel imaging system. Processing of streptavidin blots was similar. Following Ponceau imaging, blots were blocked in blocking buffer for 30 min at room temperature, immersed in blocking buffer supplemented with streptavidin-HRP (1:3000 dilution, ThermoFisher Scientific, RRID:[AB_2619743](https://scicrunch.org/resolver/AB_2619743)) at room temperature for 15 min, rinsed with blocking buffer five times for 5 min each, developed and imaged using the Clarity reagent and an Alpha Innotech gel imaging system.

The data in these experiments ([Figures 1C](#fig1){ref-type="fig"} and [3D](#fig3){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) were also reproduced for quality control prior to quantitative PCR and sequencing.

Quantitative RT--PCR {#s4-7}
--------------------

For quantitative RT--PCR (qRT--PCR, [Figure 1---figure supplement 1A,C](#fig1s1){ref-type="fig"}, [Figure 3E](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) RNA samples (isolated as described below) were reverse transcribed using the SuperScript III Reverse Transcriptase kit (ThermoFisher Scientific), priming with random hexamers (ThermoFisher Scientific) according to the manufacturer's protocol. Samples were diluted with water, mixed with gene specific primers ([Supplementary file 5C](#supp5){ref-type="supplementary-material"}), and Rox-normalized FastStart Universal SYBR Green Master Mix (Roche Applied Sciences, Penzberg, Germany), and aliquotted into 384-well plates. qRT--PCR was performed on an Applied Biosystems 7900HT Fast real time PCR instrument, in quadruplicate. All threshold cycles (C~t~, calculated per well) and efficiencies (*ε*, calculated per primer pair), were calculated from 'clipped' data, using Real time qPCR Miner ([@bib74]). Primer pairs with average efficiencies below 90%---measured by qPCR Miner in at least three biological replicates, four technical replicates each---were omitted from further use. Raw C~t~ values were corrected to account for the differences in sample volume, and percent yields were calculated via the ΔCt method:$$yield = 100 \times \left( 1 + \varepsilon)^{{\mathrm{\Delta}C}_{t}} \right.$$

...where in, $\Delta C_{t} = C_{t_{input}}\ corr - C_{t_{RIP}}\ corr$

Experimental uncertainties were calculated as described previously ([@bib65]). Given D = A--B, uncertainly was calculated using the formula:$$\sigma_{D} = \sqrt{\left( \sigma_{A} \right)^{2} + \left( \sigma_{B} \right)^{2}}$$

...wherein σ~A~ and σ~B~ are the measurement errors of A and B, respectively. For P, the product or quotient of values A and B, uncertainty was calculated using the formula:$$\sigma_{P} = P \times \sqrt{\left( \frac{\sigma_{A}}{A} \right)^{2} + \left( \frac{\sigma_{B}}{B} \right)^{2}}$$

The uncertainties of other functions, *f(x)*, were calculated using the first derivative approximation:$$\sigma_{f(x)} = \sigma_{x} \times f'\left( x \right)$$

Sample sizes were determined in accordance with standard practices used in similar experiments in the literature; no sample-size estimates were performed to ensure adequate power to detect a prespecified effect size. Experiments were neither randomized nor blinded to experimental conditions. Each samples contained four technical replicates and no samples were excluded from analysis. Significance testing: Student's two-tailed t-test.

APEX-RIP, Part I: optimized in situ biotinylation and crosslinking {#s4-8}
------------------------------------------------------------------

Stable-expression HEK 293T cells were grown to 90% confluency in 6-well plates, as described above. Cells were incubated in fresh growth media supplemented with 500 μM Biotin Phenol (BP) ([@bib61]); also available from Iris Biotech GmbH, Marktredwitz, Germany) for 30 min at 37°C, after which cells were moved to room temperature and H~2~O~2~ was added to a final concentration of 1 mM. After 1 min, media was aspirated, and the APEX labeling reaction was quenched by addition of 2 mL azide-free quenching solution (10 mM ascorbate and 5 mM Trolox, in PBS), and further incubation at room temperature for 1 min. Thereafter, the liquid phase was aspirated, and cells were crosslinked by addition of 5 mL crosslink-quench solution (0.1% (v/v) formaldehyde, 10 mM sodium ascorbate, and 5 mM Trolox, in PBS). After 1 min, media were aspirated, and cells were again incubated in 5 mL fresh crosslink-quench solution, for 9 min at room temperature, with gentle agitation. The crosslinking reaction was terminated by addition of glycine (1.2 M stock, in PBS) to a final concentration of 125 mM, and gentle agitation for 5 min at room temperature. Cells were washed twice with 2 mL room-temperature PBS, harvested by scraping, pelleted by centrifugation, and either processed immediately or flash frozen in liquid nitrogen and stored at --80°C before further analysis.

APEX-RIP, Part II: Cell lysis, streptavidin bead enrichment of biotinylated material and RNA isolation {#s4-9}
------------------------------------------------------------------------------------------------------

Unless otherwise noted, all buffers used during RNA isolation were supplemented to 0.1 U/ μL RNaseOUT (ThermoFisher Scientific), 1 × EDTA free proteinase inhibitor cocktail (ThermoFisher Scientific) and 0.5 mM DTT, final. Labeled, crosslinked cell pellets were thawed on ice (when necessary), and lysed by incubation in 1 mL ice-cold RIPA buffer, supplemented with 10 mM ascorbate and 5 mM Trolox, for 5 min at 4°C with end-over-end agitation. Samples were then sheared as described previously ([@bib25]) using a Branson Digital Sonifier 250 (Emerson Industrial Automation, St. Louis, MO) at 10% amplitude for three 30 s intervals (0.7 s on +1.3 s off), with 30 s resting steps between intervals. Samples were held in ice-cold metal thermal blocks throughout sonication. Lysates were then clarified by centrifugation at 15,000 × *g* for 5 min at 4°C, moved to fresh tubes and each diluted with 1 mL Native lysis buffer (NLB: 25 mM Tris pH 7.4, 150 mM KCl, 0.5% NP-40, 5 mM EDTA), supplemented with ascorbate and trolox. For each sample, 20% was removed as 'input;' to the remainder was added 50 μL of streptavidin-coated magnetic bead slurry (ThermoFisher Scientific ) that had been equilibrated by two washes in 1:1 RIPA:NLB. Samples were incubated for 2 hr at 4°C with end-over-end agitation. Beads were subsequently washed with the following series of buffers (1 mL each, 5 min per wash, 4°C, with gentle end-over-end agitation): (1) RIPA buffer, supplemented with trolox and ascorbate, (2) RIPA buffer without radical quenchers, (3) high salt buffer (1 M KCl, 50 mM Tris, pH 8.0, 5 mM EDTA), (4) urea buffer (2 M Urea, 50 mM Tris, pH 8.0, 5 mM EDTA), (5) RIPA Buffer, (6) 1:1 RIPA: NLB, (7) NLB, and (8) TE (10 mM Tris, pH 7.4, 1 mM EDTA).

Enriched RNAs were released from the beads by proteolysis in 100 μL of Elution Buffer (2% N-lauryl sarcoside, 10 mM EDTA, 5 mM DTT, in 1X PBS, supplemented with 200 μg proteinase K (ThermoFisher Scientific) and 4 U RNaseOUT) at 42°C for 1 hr, followed by 55°C for 1 hr, as previously described ([@bib25]). Eluted samples were cleaned up using Agencourt RNAClean XP magnetic beads (Beckman Coulter, Pasadena, CA), following the manufacturer's 1.5 mL tube format protocol, and eluted into 85 μL H~2~O. Thereafter, contaminating DNA was removed by digestion with 5 U RQ1 RNase-free DNase I (Promega, Fitchburg, WI) in 100 μL of the manufacturer's supplied buffer (1X final concentration) at 37°C for 30 min. Purified RNAs were again cleaned up using Agencourt RNAClean XP magnetic beads, as above, and eluted into 30 μL H~2~O. The concentration and integrity of all samples was measured using an Agilent 2100 Bioanalyzer, following the 'RNA Nano' or 'RNA Pico' protocols, where appropriate. Samples were not heat-cooled prior to loading Bioanalyzer chips.

Alternate APEX-RIP biotinylation and crosslinking protocols {#s4-10}
-----------------------------------------------------------

For Mito-APEX2 experiments ([Figure 1](#fig1){ref-type="fig"}), we followed a BP--then--crosslinking protocol that omitted the discrete radical quenching step ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, *bottom*). Briefly, cells were grown and APEX-labeled as described above. Following the 1 min incubation in H~2~O~2~, cells were immediately treated with 5 mL crosslink-quench solution for one minute at room temperature, to simultaneously quench the APEX2 BP labeling reaction and initiate formaldehyde crosslinking. The liquid phase was aspirated, and cells were incubated in 5 mL of fresh crosslink-quench for two additional 1 min incubation steps, followed by a third, 8 min incubation at room temperature with gentle agitation.

Thereafter, crosslinking was terminated by the addition of glycine, and cells were harvested as described above. All subsequent steps (streptavidin bead enrichment, library prep, etc) proceeded as described above.

For the crosslinking--then--BP biotinylation protocol ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, *top*), cells were washed once with 5 mL PBS, and crosslinked in 5 mL 0.1% (v/v) formaldehyde in PBS for 10 min at room temperature, with gentle agitation. The crosslinking reaction was quenched by addition of glycine (1.2 M, in PBS) to final concentration 125 mM, and gentle agitation for 5 min at room temperature. Crosslinked cells were then washed three times with PBS and incubated with 500 μM biotin-phenol (BP) in PBS at room temperature, for 30 min. Thereafter, H~2~O~2~ was added to a final concentration 1 mM, for 1 min. The liquid phase was then removed by aspiration, and cells were washed twice with 2 mL quenching solution (5 mM Trolox, 10 mM Sodium Ascorbate, 10 mM sodium azide, in PBS). Crosslinked, labeled cells were harvested by scraping, and processed as described above.

APEX-RIP, Part III: Library preparation, sequencing, and quantification {#s4-11}
-----------------------------------------------------------------------

Purified RNA samples were depleted of ribosomal RNA using the Ribo-Zero Gold rRNA removal kit (Illumina, San Diego, CA), generally in accordance with the manufacturer's protocol. Briefly, RNA concentration and integrity were quantified on an Agilent 2100 Bioanalyzer, using 'RNA Pico' and, where appropriate, 'RNA Nano' kits. Samples were not concentrated prior to rRNA depletion, which can accommodate a maximum input volume of 17 μL. Therefore, samples with total input masses of ≤ 20 ng or 20--100 ng were mixed with 1 μL or 2 μL of Ribo-Zero rRNA Removal Solution, respectively, in 1x RiboZero Reaction Buffer, at a final volume of 20 μL. Reaction mixes were incubated at 68°C for 10 min, followed by 25°C for 5 min more, and thereafter added to 32.5 μL magnetic beads (90 μL bead slurry; washed with water and equilibrated in Magnetic Bead Resuspension Buffer, supplemented with RiboGuard RNase Inhibitor) by extensive pipetting. Binding reactions were incubated at room temperature for 5 min, gently vortexed for 5 s, and incubated for 5 min at 50°C, in a thermocycler. The supernatant, containing rRNA-depleted RNA, was diluted in water to 50 μL final volume, cleaned up with 50 μL Agencourt RNAClean XP beads and eluted with 19.5 μL of Elute, Prime, Fragment mix from the TruSeq RNA sample preparation kit, v2 (Illumina). Thereafter, libraries were prepared using the TruSeq RNA sample preparation kit, according to the manufacturer's instructions, starting from 'Incubate RFP' step. Each library was given a unique index during synthesis. Library concentration was measured, and quality confirmed, on an Agilent 2100 Bioanalyzer, using 'DNA High Sensitivity' kits.

While we did not explicitly include an RNA size-selection step in our library syntheses, we anticipate that smaller RNAs (tRNAs, snoRNAs, etc) would be relatively undersampled during our workflow. The mixing ratios used at all Agencourt bead-based cleanup steps (i.e. after reverse-crosslinking, during rRNA depletion, and throughout the early steps of library synthesis) disfavor the binding of such smaller species. For tRNAs, compact structure and post-transcriptional modifications can hinder amplification, making absolute quantification difficult ([@bib75]). Finally, the RNA fragmentation and library amplification steps have been optimized to generate libraries an average length of \~270 bp, as verified by BioAnalyzer. We assume that such undersampling applies equally to our input and RIP libraries, allowing us to compute fold enrichments, if not absolute abundances, for smaller RNAs that have somehow escaped de-enrichment (e.g. [Figure 1D--E](#fig1){ref-type="fig"}).

Indexed libraries were pooled in equimolar concentrations, with no more than ten libraries per pool, and subjected to 50 cycles of paired end sequencing, followed indexing, on two lanes of Illumina HiSeq 2500 flow cells, run in rapid mode (Genomics Core, Broad Institute of Harvard and MIT).

In general, three biological replicates for each construct were performed. Two biological replicates were performed for the mito-APEX experiment in [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}.

As a basis of comparison, we here summarize the salient differences between our library preparation method, and those used in the alternative subcellular transcriptomics papers cited.

For the HEK 293T nuclear-cytoplasmic transcriptome datasets ([@bib67]), RNA isolation, library preparation and sequencing methods for the nuclear-cytoplasmic HEK293T dataset were generally similar to our own. Key differences include: (1) the analogous 'pre-enrichment' samples were obtained by Qiagen RNA extraction of live cells, (2) samples were not subjected to reverse-crosslinking or proteinase K treatment, and (3) following DNAse treatment, and RiboZero rRNA removal, samples were purified by ethanol precipitation with a glycogen carrier. Raw data were re-mapped and quantified in-house, using the same pipeline as was used for our own (*see below*).

Datasets for both ER Fractionation-Sequencing ([@bib60]) and proximity-restricted ribosome profiling ([@bib31]) experiments were acquired by isolating ribosome-protected small RNA fragments, using methods that markedly differed from our own. In each case, fractionated and/or biotinylated polysomes were isolated and treated with RNAse. Monosome-protected RNA fragments were purified by gel electrophoresis, ligated to sequencing adaptors and reverse transcribed. Thereafter, Frac-Seq libraries were PCR amplified and subjected to SOLiD sequencing; Ribosome profiling libraries were circularized before library amplification and subjected to single-end Illumina sequencing. We did not re-analyze data from these experiments: transcript quantifications were used as reported.

Quantification of RNA abundances and folds enrichment; Assembly of true positive and false positive lists {#s4-12}
---------------------------------------------------------------------------------------------------------

Deep sequencing reads were mapped to human genome assembly hg19 using TopHat v2.1.1 ([@bib33]), RRID:[SCR_013035](https://scicrunch.org/resolver/SCR_013035)), with the flags, '\--no-coverage-search' and '\--GTF gencode.v19.annotation.gtf'. Gene expression was quantified against the Gencode v19 reference transcriptome (gencode.v19.annotation.gtf, genecodegenes.org) with Cufflinks v2.2.1. ([@bib69]), RRID:[SCR_014597](https://scicrunch.org/resolver/SCR_014597)), assessing the statistical significance of differential expression via CuffDiff2 (RRID:[SCR_001647](https://scicrunch.org/resolver/SCR_001647)), with the flags, '\--dispersion-method per-condition' and '\--seed 42'.

No explicit filtering was imposed to mask the quantification of any RNA species: although nuclear-encoded tRNA, 5.8S, 18S, and 28S rRNA genes are absent from the Gencode reference transcriptome, and are hence opaque to our analysis, all other transcripts were quantified in an unbiased manner. Each RIP experiment was quantified independently. All Seq data will be made available through GEO under accession GSE106493.

Fold enrichments were calculated as follows:$${log}_{2}foldchange = {log}_{2}\left\lbrack \frac{{AverageFPKM}_{Poststreptavidinenrichment}}{{AverageFPKM}_{Prestreptavidinenrichment}} \right\rbrack$$

Significantly enriched genes in APEX-RIP, nuclear--cytosolic fractionation ([@bib67]), and ER-fractionation ([@bib60]) datasets were called as follows. RNAs with *p*-values greater than 0.05 (measured in CuffDiff, as described above) were removed from analysis. For ER-fractionation dataset ([@bib60]), RNAs with RPKM lower than 10 were filtered out. The remaining RNAs were then used to determine the enrichment threshold cutoffs, using Receiver Operating Characteristic (ROC) analysis ([@bib20]), employing sets of true-positive and false-positive genes identified as described below. At each fold enrichment value, the true positive rate (TPR---the fraction of true positive genes identified as being enriched) and the false positive rate (FPR---the fraction of false positive genes identified as being enriched) were calculated. The fold enrichment value that maximizes the difference of these values (TPR--FPR) was chosen as the fold enrichment cutoff. In mitochondrial and ER-associated APEX-RIP experiments, ROC analysis was based on log~2~ fold enrichment values comparing pre- and post-enrichment RNA abundances; in the nuclear-cytoplasmic experiment, it was based on calculated log~2~ fold enrichment values comparing post-enrichment APEX2-NLS and APEX2-NES abundances.

The true and false positive gene sets needed for ROC analysis were defined as follows:

1.  For mitochondrial APEX-RIP, true positives corresponded to the thirteen mitochondrial-encoded mRNAs; false positive RNAs corresponded to nuclear-encoded long non-coding RNAs.

2.  For the nuclear and cytosolic partitioning experiment, the true positive list was defined as HEK293T-expressed long non-coding RNAs; the false positive list was the list of ER proximal RNAs ([Supplementary file 3D](#supp3){ref-type="supplementary-material"}) ([@bib31]).

3.  For ER-APEX-RIP, true positive genes were defined using data from ER-localized proximity-dependent ribosome profiling ([@bib31]), applying a 'low-stringency' selection approach ([Supplementary file 3D](#supp3){ref-type="supplementary-material"}, 'Low-stringency ER list'). Namely, true-positives corresponded to all RNAs with input RPKM ≥5.0, input count ≥12, and log~2~(fold enrichment)≥0.904 (determined by ROC analysis) combined with all other HEK293T-expressed genes that were predicted by Phobius as having secretory signals, but which were absent from MitoCarta ([@bib55]). False positive RNAs were defined as all HEK293T-expressed genes lacking secretory signals, as predicted by Phobius ([@bib36]), SignalP ([@bib57]), and TMHMM ([@bib35]).

Coverage and specificity analysis of nuclear, cytosolic, and ER-proximal RNAs {#s4-13}
-----------------------------------------------------------------------------

To estimate the coverage (recall) and specificity of APEX-RIP at each subcellular compartment, we assembled lists of established target and off-target genes tailored for that compartment.

For analysis of the nuclear--cytosolic datasets ([Figure 2F](#fig2){ref-type="fig"}), our reference nuclear gene list comprised 827 lncRNAs with average RNA pre-enrichment abundances of 1.0 or greater. Our reference off-target list comprised the set of 1260 'Low-stringency' ER-proximal RNAs defined using proximity-restricted ribosome profiling ([@bib31]), as described above ([Supplementary file 3D](#supp3){ref-type="supplementary-material"}, 'Low-stringency ER list').

For coverage analysis of the ER-proximal datasets ([Figure 4D](#fig4){ref-type="fig"}), our reference gene list comprised 71 mRNAs encoding ER-resident proteins ([Supplementary file 3E](#supp3){ref-type="supplementary-material"}). For specificity analysis ([Figure 4C,E](#fig4){ref-type="fig"}) a list of 'high-stringency' true positive genes ([Supplementary file 3D](#supp3){ref-type="supplementary-material"}, 'High-confidence ER list') was assembled using the ER-localized proximity-dependent ribosome profiling data ([@bib31]), applying an input count cutoff of ≥100 and a log~2~(fold enrichment) cutoff of ≥0.904 (determined by ROC analysis, as above). The reference off-target list used in this analysis comprised 8855 mRNAs lacking secretory annotation, as assessed using Phobius, TMHMM, and SignalP, and which lacked the GOCC terms 'Endoplasmic reticulum,' 'Golgi,' 'membrane,' and 'extracellular' ([@bib3]).

For analysis of contaminants in ER datasets ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), the mRNAs that lacked predicted secretory annotation (assessed by Phobius, TMHMM, and SignalP, and by an absence of the GOCC terms 'Endoplasmic reticulum,' 'Golgi,' 'membrane,' and 'extracellular') were submitted to DAVID Bioinformatics analysis ([@bib27]), RRID:[SCR_003033](https://scicrunch.org/resolver/SCR_003033)). Only Gene Ontology terms that were enriched with *p*-values less than 0.05 ---relative to the human background---are shown.

Identification of candidate lamina-localized RNAs {#s4-14}
-------------------------------------------------

To obtain an initial list of potential laminar RNAs, we identified transcripts that were significantly enriched both within the nucleus and near the ER membrane ([Figure 5C](#fig5){ref-type="fig"}). We manually curated our lists of APEX-RIP nuclear-localized and ER-associated RNAs (derived from ROC- and *p-*value analysis---*see above*---without further modification; [Supplementary files 2A](#supp2){ref-type="supplementary-material"} and [3A](#supp3){ref-type="supplementary-material"}), to identify transcripts that were significantly enriched in both. This resulted in a set of 441 overlapping RNAs ([Supplementary file 4B](#supp4){ref-type="supplementary-material"}), which we classified into transcript types according to standard GENCODE nomenclature. Statistically significant enrichment of overlapping RNAs in each class was calculated by hypergeometric test.

Of the initial 441 candidate RNAs, 337 correspond to mRNAs encoding secretory proteins, annotated as described above. However, since expression was measured at the gene level, and did not quantify individual RNA isoforms (*see above*) the apparent abundance of each gene stems from its mature and all immature (e.g. partially spliced) transcripts. Hence, the 337 secretory mRNAs in our overlapping set might be regarded as potential false positives, corresponding to cases where we have measured mature mRNAs near the ER surface, and partially processed precursor species in the nucleus, and not discrete species that reside at the interface of the nucleus and ER (i.e., the lamina). For this reason, we encourage omitting these genes in subsequent analysis of potential laminar RNAs ([Figure 5D](#fig5){ref-type="fig"}).

Significance {#s4-15}
------------

RNA subcellular localization is a critical factor that influences a wide array of biological processes, ranging from *Drosophila* embryogenesis to mammalian neuronal signaling. However, while this spatial layer of transcriptome regulation has been characterized in a handful of contexts, a broader understanding of its overall extent, the factors governing its establishment, and its impact on biological function, remain inchoate. The limitations hindering this understanding have been largely technical, since conventional methods---such as fluorescence in situ hybridization (FISH) and Fractionation-Sequencing ('Frac-Seq')---depend upon specialized reagents and protocols that can limit throughput and general applicability. To address this fundamental need, we have developed a new strategy---APEX-RIP---which uses a simple toolkit and workflow to map the transcriptomes of discrete subcellular compartments at high depth and spatiotemporal resolution. APEX-RIP uses the engineered ascorbate peroxidase APEX to biotinylate proteins within a target subcellular compartment in live cells; these affinity-tagged proteins are then chemically crosslinked in situ to nearby RNAs. When applied to a variety of membrane-enclosed and membrane-adjacent compartments, the APEX-RIP strategy exhibited target specificity and coverage rivaling or exceeding those attained by conventional fractionation-sequencing-based approaches, at a depth far exceeding those attainable by imaging-based methods. Furthermore, APEX-RIP can be applied to compartments that are recalcitrant to conventional biochemical purification. Given the superior precision, flexibility, and ease of this approach, we anticipate that APEX-RIP will provide a powerful tool for dissecting RNA subcellular localization in a broad range of biological contexts.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R01-CA186568 to Alice Y Ting.

-   http://dx.doi.org/10.13039/100005492Stanford University to Alice Y Ting.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health U01-DA040612 to John L Rinn.

We thank Jeffrey Martell for valuable experimental advice, Ozan Aygun for the curated ER protein list and assistance generating APEX2-NLS and HRP-KDEL stable cell lines, Chinmay Shukla and Furqan Fazal for valuable computational advice, and members of the Ting and Rinn labs for their constructive insights and critiques. Funding was provided by the NIH (R01-CA186568 to AYT and U01 DA040612 to JLR) and Stanford (to AYT).

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Data curation, Validation, Investigation, Visualization, Methodology, Writing---original draft, Writing---review and editing.

Conceptualization, Validation, Investigation, Visualization, Methodology, Writing---original draft, Writing---review and editing.

Formal analysis, RNA-Seq analysis.

Supervision, Funding acquisition, Writing---review and editing.

Conceptualization, Supervision, Funding acquisition, Visualization, Methodology, Writing---original draft, Writing---review and editing.

Additional files {#s6}
================

10.7554/eLife.29224.014

###### Mitochondrial APEX-RIP Data.

\(A\) RNAs enriched by mito-APEX2-RIP. (B) Unfiltered mito-APEX-RIP RNA-Seq data. (C) Column definitions.

10.7554/eLife.29224.015

###### Nuclear and Cytosolic APEX-RIP Data.

\(A\) APEX2-RIP-enriched nuclear RNAs. (B) APEX2-RIP-enriched cytosolic RNAs. (C) Unfiltered APEX-RIP RNA-Seq data. (D) Unfiltered nuclear and cytosolic fractionation-seq data ([@bib67]). (E) Fractionation-Seq-enriched Nuclear RNAs. (F) Fractionation-Seq-enriched cytosolic RNAs. (G) lncRNAs used to determine coverage analysis ([Figure 2F](#fig2){ref-type="fig"}). (H) Column definitions.

10.7554/eLife.29224.016

###### KDEL-RIP Data (ER-proximal RNAs).

\(A\) KDEL-RIP-enriched ER-proximal RNAs. (B) Unfiltered KDEL-RIP RNA-Seq data. (C) ER-associated RNAs enriched by Fractionation-Seq ([@bib60]). (D) ER-associated RNAs enriched by proximity-dependent ribosome profiling ([@bib31]). (E) True positive list: RNAs encoding established ER-resident proteins. (F) Column definitions.
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###### Additional analysis of ER and nuclear datasets.

\(A\) Mitochondrial mRNAs (nuclear-encoded) enriched at the ER membrane. (B) RNAs that may be enriched at the nuclear lamina. (C) Column definitions.

10.7554/eLife.29224.018

###### Materials used in this study.

\(A\) Genetic constructs used in this study. (B) Antibodies used for immunofluorescence. RRID: Research Resource Identifier (<https://scicrunch.org/resources>). (C) qRT-PCR primers used in this study. (D) Column definitions.
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Major datasets {#s7}
--------------

The following dataset was generated:

Pornchai KaewsapsakDavid Michael ShechnerWilliam MallardJohn L RinnAlice Y Ting2017Live-cell mapping of organelle-associated RNAs via proximity biotinylation combined with protein-RNA crosslinking<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106493>Gene Expression Omnibus (accession no: GSE106493)

The following previously published datasets were used:

Sultan MAmstislavskiy VRisch TSchuette MDökel SRalser MBalzereit DLehrach HYaspo ML2014Influence of RNA extraction methods and library selection schemes on RNA-seq data<https://www.ebi.ac.uk/ena/data/view/PRJEB4197>Publicly available at the EBI European Nucleotide Archive (accession no: PRJEB4197)

Jan CHWilliams CCWeissman JS2014Principles of ER Co-Translational Translocation Revealed by Proximity-Specific Ribosome Profiling<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61012>Gene Expression Omnibus (accession no: GSE61012)

Reid DWNicchitta CV2012Ribosome footprinting in the cytosol and endoplasmic reticulum<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31539>Gene Expression Omnibus (accession no: GSE31539)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Live-cell mapping of organelle-associated RNAs via proximity biotinylation combined with protein-RNA crosslinking\" for consideration by *eLife*. Your article has been favorably evaluated by Vivek Malhotra (Senior Editor) and three reviewers, one of whom served as Guest Reviewing Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This manuscript presents a new method, APEX-RIP, for detecting RNAs enriched in subcellular compartments. The method is an extension of this lab\'s previous method for isolation of protein complexes following in vivo proximity biotinylation using the engineered APEX2 enzyme. Here, APEX2 or HRP biotin labeling of proteins is combined with cross-linking and immunoprecipitation of RNA to probe the transcriptomes of specific subcellular locales. The method is not restricted to mRNAs, but can identify non-coding RNAs as well. The authors apply the method to map the RNA neighborhood compositions for cytosolic, nuclear, mitochondrial and ER cellular compartments in human HEK293 cells. The authors argue that the method advances the field of RNA localization and provides better temporal resolution, recall and specificity than current techniques including proximity-dependent ribosome profiling and subcellular fractionation-seq. To demonstrate the utility of the data, the authors offer interesting hypotheses about mitochondrial-ER junction and nuclear lamina RNAs, but these are highly speculative and not adequately supported by the data currently provided. There are also concerns about the spatial specificity and resolution of the method and the ability to discriminate contaminants from bona fide localization as well as the applicability to non-membranous compartments. Overall, the paper is well written, and data are presented that generally support the potential of APEX-RIP as a useful method to characterize subcellular transcriptomes. We have the following suggestions to better validate the method and improve the manuscript.

Essential revisions:

1\) A major concern relates to the spatial specificity in membrane-free subcellular regions. The APEX-RIP methodology appears to work well for tightly bounded compartments (e.g. the inner mitochondrial matrix), but its specificity declines rapidly as compartments become less well defined. While the authors do mention this limitation in the Discussion, the message of the paper should be rebalanced towards clarifying these drawbacks. In all approaches the authors detect significantly more RNAs than previous methods and explain this solely with higher sensitivity of the approach without adequately validating this claim. In particular, they fail to address the possibility that a certain proportion of the hits may be false positives resulting from diffusion of biotinylated proteins prior to crosslinking. Contrary to what the authors state that capture of RNA does not happen \"during a one-minute reaction\". Instead, those proteins that are biotinylated during a one-minute reaction are in principle free to diffuse and interact with additional RNA molecules for several minutes until crosslinking is complete. For example, many nuclear RNA-binding proteins that are presumably targets of APEX2-NLS and between the nucleus and cytoplasm. Given that nuclear shuttling occurs on the msec time scale but there is a minute between treatment with peroxide and crosslinking, and that these relatively abundant proteins directly contact RNA, it seems likely that a significant fraction of the processed mRNAs found in the APEX2-NLS experiment may not be nuclear RNAs at all, but cytoplasmic RNAs crosslinked to RNA-binding proteins that were biotinylated in the nucleus but transited to the cytoplasm. Similarly, the authors find that targeting APEX/HRP to the lumen of the ER results in much higher specificity of RNA recovery than when it is targeted to the ER surface. Presumably this is connected to the more limited diffusion of proteins that reside in the ER lumen vs. the surface in the period immediately following biotin labeling.

Additionally, given the relatively mild and slow crosslinking conditions used, it seems inconsistent to assert that other RNA localization methods \"fundamentally lack temporal precision \[because\] each requires extensively fixing and permeabilizing cells prior to data collection, during which time diffusion or the loss of cellular integrity can perturb endogenous RNA localization.\" The authors then state that \"APEX-RIP is not encumbered by any of these constraints\", but one could argue that during a 10 minute formaldehyde crosslinking procedure at room temperature, many biotinylated proteins are likely to keep diffusing and interacting with additional RNA molecules for some time. Have the authors considered alternatives to formaldehyde crosslinking e.g. UV crosslinking, which could be performed on ice in a shorter time, thus potentially limiting diffusion of biotinylated proteins?

2\) Another potential limitation of the method that should at least be discussed is applicability of the method to animal level analysis, for example eggs, embryos, or the nervous system of an intact animal, where mRNA localization is a crucial regulatory mechanism.

3\) Another major concern is discriminating contaminants as opposed to identifying novel subcellular RNA localization. Regarding the result (subsection "Hypotheses from ER and nuclear APEX-RIP datasets", first paragraph) that 141 of the 2635 mRNAs in the ERM dataset code for mitochondrial proteins, it isn\'t clear why these were not identified as conspicuous \"mitochondrion\" contaminants when ontology analysis was done in the fractionation comparison. This analysis identified only 13 mitochondrion by ER fractionation-seq. The same might be said for the overlap of ER enriched and APEX-NLS enriched RNAs to arrive at the nuclear lamina localized RNA candidates. Why are these candidates not detected as contaminants in either individual set?

4\) The novel hypotheses generated from the APEX-RIP data (mito-ER junction and nuclear lamina RNAs) are potentially interesting but in both cases highly speculative. Both ideas would be greatly strengthened if the authors could validate that some APEX-RIP candidate RNAs indeed localize to the suggested sites (e.g. by FISH or live RNA tracking).

5\) The analysis of RNAs potentially associated with the nuclear lamina seems problematic. Whereas 14% of the set of nuclear RNAs detected overlap with the ER-associated RNAs, only 6% of the lncRNAs overlap. Thus, the lncRNAs are under-represented in the population of nuclear RNAs that could be associated with the lamina. The caveat that RNAs identified as nuclear may not actually be nuclear further weakens this analysis.

6\) In the third paragraph of the Discussion, and at several other places of the manuscript, the authors make claims such as: \"Compared to fractionation-based technologies, APEX-RIP offers superior accuracy\". This seems like an over-interpretation based on the evidence presented, especially for the analyses of nucleo-cytoplasmic RNA distribution profiles. Firstly, the authors appear to draw this conclusion by comparing APEX-RIP and Frac-seq data from different cell lines (e.g. [Figure 2F](#fig2){ref-type="fig"}). While it is likely that the nucleo-cytoplasmic localization of RNAs may exhibit a high degree of similarity between cell lines, comparison of results generated from the same cell lines would seem important to draw such conclusions. Second, the detection of ER mRNAs within the nucleus in Frac-seq data, but not APEX2-NLS samples, could simply underline the ability of the Frac-seq approach to purify and detect pre-mRNAs. Do the authors detect such species within APEX2-NLS RNA-seq dataset? Is read coverage of intronic regions comparable to that observed with nuclear Frac-seq?

7\) The authors provide evidence that APEX-RIP captures RNAs with lower abundances than alternative approaches do, but it would be nice to have some sort of estimate of the limit of detection. Furthermore, there is no discussion for any of the experiments about false negatives.

8\) Regarding RNAseq library preparation and data analysis, it would be useful to include more detail in both the Materials and methods section and the main text to demonstrate that their sequencing datasets and the different reference datasets are indeed directly comparable. Specifically, in the Materials and methods section the authors should include the dataset IDs for the specific ENCODE datasets and explain whether they as well as the other mentioned datasets were generated using comparable library preparation and sequencing methods. While the authors specifically mention lncRNAs, it is unclear how other, often highly abundant, non-protein coding RNAs were treated in the analysis. While this should be explained in detail in the Materials and methods, it would be useful to also include a brief description in the main text.

9\) For IF assays to confirm proper APEX/HRP fusion subcellular targeting, co-labeling with organelle specific markers should be shown.

10.7554/eLife.29224.031

Author response

> Essential revisions:
>
> 1\) A major concern relates to the spatial specificity in membrane-free subcellular regions. The APEX-RIP methodology appears to work well for tightly bounded compartments (e.g. the inner mitochondrial matrix), but its specificity declines rapidly as compartments become less well defined. While the authors do mention this limitation in the Discussion, the message of the paper should be rebalanced towards clarifying these drawbacks.

Inspired by this critique, we have edited the manuscript to rebalance the message of the paper. We now make clear at multiple points within the revised text (Introduction, Results, and Discussion) that APEX-RIP has drawbacks, most notably lower spatial specificity in compartments that are less well defined. However, we would like to note that APEX-RIP *was* able to successfully map the transcriptome of an "open" compartment (the cytosolic face of the ER), though doing so entailed biotinylating that organelle's lumen. Given that many biological processes occur in membrane-proximal regions, we feel that this approach should still have broad utility and be helpful to a wide range of biologists.

> In all approaches the authors detect significantly more RNAs than previous methods and explain this solely with higher sensitivity of the approach without adequately validating this claim.

There are two possible reasons for why we detect more RNAs than previous approaches. One is that we have higher sensitivity. Another is that we recover more non-specific hits (i.e., have more false positives). We believe that the data presented in this study support the first explanation rather than the second. We note:

1\) New [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"} shows that our method is indeed more sensitive: APEX-RIP was able to recover established, truepositive RNAs of lower abundances than could either fractionation-Seq or proximity-dependent ribosome profiling.

2\) For each compartment, we analyze the specificity of the resulting dataset in the best way that we know how. [Figure 2F](#fig2){ref-type="fig"}; [Figure 4C](#fig4){ref-type="fig"} show that our specificity is not worse than other methods; in some cases, it is noticeably better. For example, our ER dataset is 96.5% specific (96.5% of enriched mRNAs encode transmembrane or secreted proteins), while ER fractionation-seq analyzed in an identical manner is 91% specific.

3\) We also directly calculate sensitivity for each dataset, which we term "coverage", or recall of expected RNAs. In [Figure 4D](#fig4){ref-type="fig"} for example, we have better recall/coverage/sensitivity than do either fractionation-seq or proximity-dependent ribosome profiling, analyzed in an identical fashion.

4\) When we take a closer look at the RNAs that we recover that other methods do not (i.e., the non-overlapping part of the Venn diagram in [Figure 4E](#fig4){ref-type="fig"}), we do not observe a substantial reduction in specificity, as measured by prior annotation. For example, for the ER, we detect 1281 RNAs that were missed by both Fractionation-Seq and proximity-dependent ribosome profiling. The specificity of mRNAs in this group is 93.4%, close to the specificity of the entire dataset of 2672 RNAs (of which 2494 are mRNAs). This strongly suggests that the additional RNAs we capture are still specific hits, and that we are not collecting more hits at the expense of specificity.

5\) Comparing to ribosome profiling in particular, it makes sense that we should capture more, since we can enrich non-coding or silent mRNAs whereas their method cannot.

> In particular, they fail to address the possibility that a certain proportion of the hits may be false positives resulting from diffusion of biotinylated proteins prior to crosslinking. Contrary to what the authors state that capture of RNA does not happen \"during a one-minute reaction\". Instead, those proteins that are biotinylated during a one-minute reaction are in principle free to diffuse and interact with additional RNA molecules for several minutes until crosslinking is complete. For example, many nuclear RNA-binding proteins that are presumably targets of APEX2-NLS and between the nucleus and cytoplasm. Given that nuclear shuttling occurs on the msec time scale but there is a minute between treatment with peroxide and crosslinking, and that these relatively abundant proteins directly contact RNA, it seems likely that a significant fraction of the processed mRNAs found in the APEX2-NLS experiment may not be nuclear RNAs at all, but cytoplasmic RNAs crosslinked to RNA-binding proteins that were biotinylated in the nucleus but transited to the cytoplasm.

We thank the reviewer for pointing out this very legitimate concern, which has prompted us to perform a new set of experiments, shown in new [Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"} of the revised manuscript. Briefly, if a sizeable portion of biotinylated proteins-sufficient to distort our sequencing data-shuttle between the nucleus and cytosol during the "dead time" of our experiment, it should be possible to detect this redistribution by imaging. However, when monitoring the localization of biotinylated species during the course of the 17-minute biotinylation/formaldehyde crosslinking/quenching steps, we observed no significant loss of signal from within the compartment of origin (here, the nucleus) or concomitant increase in signal in the adjoining compartment (here, the cytosol; *p-*value, comparing time points = 0.374). From these data, we believe that it is unlikely that proteins biotinylated in the nucleus shuttle into the cytosol and give non-specific RNA capture to a significant degree. This claim is also supported by the RNA-Seq data itself, which shows minimal enrichment of cytosolic contaminants (e.g., ER-associated mRNAs from Jan et al.) in our nuclear APEX-RIP dataset.

> Similarly, the authors find that targeting APEX/HRP to the lumen of the ER results in much higher specificity of RNA recovery than when it is targeted to the ER surface. Presumably this is connected to the more limited diffusion of proteins that reside in the ER lumen vs. the surface in the period immediately following biotin labeling.

We have edited the text to add this point. We also believe that the increased specificity results from the difference in protein biotinylation patterns resulting from HRP-KDEL versus APEX2-ERM labeling. Because the biotin-phenoxyl radical does not cross cellular membranes, HRP-KDEL biotinylation stops abruptly at the ER membrane. In contrast, APEX-ERM biotinylation forms a "contour map" in which protein biotinylation is strongest at the ER membrane, and falls off nanometer by nanometer into the cytosol, but is still detectable even tens of nanometers away. When performing mass spec proteomics, we address this by ratioing biotinylation extent against a cytosolic APEX2-NES reference construct. Here, for APEX-RIP, we believe the formaldehyde crosslinking step captures distal RNAs in the case of APEX2-ERM biotinylation, but captures strictly ERM-proximal RNAs in the case of HRP-KDEL, whose biotinylation products are restricted to the ER lumen.

> Additionally, given the relatively mild and slow crosslinking conditions used, it seems inconsistent to assert that other RNA localization methods \"fundamentally lack temporal precision \[because\] each requires extensively fixing and permeabilizing cells prior to data collection, during which time diffusion or the loss of cellular integrity can perturb endogenous RNA localization.\" The authors then state that \"APEX-RIP is not encumbered by any of these constraints\", but one could argue that during a 10 minute formaldehyde crosslinking procedure at room temperature, many biotinylated proteins are likely to keep diffusing and interacting with additional RNA molecules for some time.

This is a valid point and we have edited the text to make the comparison to other methods more accurate. We now state that, compared to imaging-based approaches, the main advantages of APEX-RIP are (1) no use of detergent/methanol to permeabilize membranes, which can disrupt spatial relationships, and (2) full sequence data instead of just gene IDs. Hence more information can be gleaned about RNAs in specific locales.

> Have the authors considered alternatives to formaldehyde crosslinking e.g. UV crosslinking, which could be performed on ice in a shorter time, thus potentially limiting diffusion of biotinylated proteins?

We agree that APEX-CLIP is a great idea, and are interested in pursuing it in future studies. However, we have disfavored its use here for several reasons. Since APEX-catalyzed biotinylation preferentially labels the outer surface of RNPs, and since UV-induced crosslinks only form at the very cores of these complexes, we feared (though have not tested ourselves) that this disconnection between the points of labeling and contact might result in a substantial loss of signal in multi-subunit complexes. We were also concerned that various RNA•protein interactions might exhibit a range of different crosslinking efficiencies, thereby introducing bias into our sampling of the organelle-wide transcriptome (i.e. over-sampling RNAs that easily crosslinked, while undersampling those that aren't). Although the power of CLIP represents an attractive alternative, we believe that exploring this alternative falls beyond the scope of the current study.

> 2\) Another potential limitation of the method that should at least be discussed is applicability of the method to animal level analysis, for example eggs, embryos, or the nervous system of an intact animal, where mRNA localization is a crucial regulatory mechanism.

This is an excellent point. We agree that a limitation of using APEX-RIP in animals or tissue is that one must contend with BP/H2O2/formaldehyde perfusion into tissue. FISH and fractionation-Seq are more tissue-ready in this respect. We have edited the Discussion to point this out.

> 3\) Another major concern is discriminating contaminants as opposed to identifying novel subcellular RNA localization. Regarding the result (subsection "Hypotheses from ER and nuclear APEX-RIP datasets", first paragraph) that 141 of the 2635 mRNAs in the ERM dataset code for mitochondrial proteins, it isn\'t clear why these were not identified as conspicuous \"mitochondrion\" contaminants when ontology analysis was done in the fractionation comparison. This analysis identified only 13 mitochondrion by ER fractionation-seq.

The jury is still out on where nuclear-encoded, mitochondrial-resident proteins are translated. They may be translated in the open cytosol, near the outer mitochondrial membrane, at the ER membrane, or even at mito-ER contacts. Thus, for evaluating the specificity of our ERM dataset, we did not think it fair to automatically classify anything with mitochondrial annotation as a "contaminant". Instead, for the specificity analysis in [Figure 4C](#fig4){ref-type="fig"} , our approach was to classify any mRNA encoding a transmembrane protein or secreted protein (according to Phobius, TMHMM, SignalP, and GOCC annotation) as "specific" as these are reasonable candidates for translation at the ER membrane. mRNAs lacking such annotation are potentially "non-specific" as noted in the bar graph.

Specifically for the 135 mRNAs (new number, based on new analysis pipeline that takes p-values into account; see Methods) in our ER dataset that code for mitochondrial proteins, 132 of these have transmembrane annotation. So we do not count them as "non-specific". The remaining three mitochondrial genes comprise 3.4% of the total set of non-secretory/non-TM mRNAs enriched by KDEL-RIP (87 mRNAs total), which is why they aren't evident in [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"} right. For comparison, of the 114 non-secretory/non-TM mRNAs enriched by fractionation-sequencing, 13 (11.4%) exhibit mitochondrial annotation.

> The same might be said for the overlap of ER enriched and APEX-NLS enriched RNAs to arrive at the nuclear lamina localized RNA candidates. Why are these candidates not detected as contaminants in either individual set?

To address the valid critique, we will divide it into two parts: identifying contaminants in the nuclear dataset, and identifying contaminants in the ER KDEL-RIP dataset.

Finding contaminants in the Nuclear RNA experiment is difficult, largely because it's hard to know, a priori, what those contaminants should be. All RNAs start off life in the nucleus, and so all expressed genes should be represented there, to some extent. Knowing this, we have approached the issue of specificity in our nuclear APEX-RIP dataset by two means. First, we looked for enrichment of lncRNAs in the nuclear dataset, and depletion of these transcripts in the cytosolic APEX-RIP data ([Figure 2C,D](#fig2){ref-type="fig"}). Second, we looked for the depletion of mRNAs in the nuclear data, using the secretome mRNAs--a class of transcripts that should be predominantly cytoplasmic--as a proxy for mature mRNAs as a whole. In theory, we could try to expand that analysis--using *all* mature mRNAs as potential contaminants--to systematically address this issue. However, this analysis would require discrete quantification of the pre-processed and mature transcripts, for which we lack adequate sequencing depth. Given these considerations, we believe our approach -- while imperfect -- is reasonable.

The second part of the question pertains to why nuclear-localized RNAs are not classified as contaminants in the ER KDEL-RIP dataset. We have taken care to approach this issue as conservatively as possible in our analysis. For example, of the 441 RNAs that are enriched both in our nuclear and KDEL-RIP datasets, 385 are mRNAs, 337 (87.5%) of which have secretory/TM annotation. The skeptical interpretation is that the KDEL-RIP experiment has enriched mature secretory/TM mRNAs localized at the ER surface, while the NLS-RIP experiment has enriched their corresponding immature species within the nucleus. Hence, we have masked them from being potential laminar candidates.

Looking more broadly at the KDEL dataset: of the 2494 KDEL-enriched mRNAs, only 87 (3.5%) lack secretory/TM annotation -- one might initially consider these few RNAs as potential contaminants. However, 48 of these transcripts (55%) are also enriched in the NLS dataset. By comparison, only 14% of KDEL-enriched secretome mRNAs (337, out of 2407 total) are enriched in the NLS-APEX-RIP, indicating that the putative KDEL "contaminant" list is highly enriched in nuclearlocalized RNA. Given the generally high specificity of our ER-associated RNA list, and the fact that these 48 are also nuclear-enriched, we have flagged them as being candidate laminar RNAs.

In the revised manuscript, we have attempted to clarify our writing so as to emphasize these points. We furthermore explicitly discuss the possibility that some of our novel hits may be ascribed to experimental noise.

> 4\) The novel hypotheses generated from the APEX-RIP data (mito-ER junction and nuclear lamina RNAs) are potentially interesting but in both cases highly speculative. Both ideas would be greatly strengthened if the authors could validate that some APEX-RIP candidate RNAs indeed localize to the suggested sites (e.g. by FISH or live RNA tracking).

We believe that this request is beyond the scope of this work, which was submitted as a Tools and Resources article, and accordingly presents new methodology for studying RNA localization in living cells, and multiple high quality datasets that contain thousands of novel RNAs not previously associated with specific organelles (i.e., Resources). We parse the data to identify mito-ER and lamina candidates only to illustrate how the new datasets that we contribute can be mined in straightforward ways for novel hypotheses--hypotheses that are excellent starting points for new bodies of work.

Furthermore, we note that follow-up validation is not a simple matter that can be completed in 1-2 months. There are major technical considerations that suggest such follow up would be more suitable for a new study rather than as an addition to this work. First, the live RNA tracking methods suggested by the reviewer (using, for example, fluorescent dye-binding aptamers, or cassettes of fluorescently-labeled RNA-binding proteins) require either expressing the target RNA as a chimeric transgene -- which might not necessarily recapitulate the expression regime and subcellular localization of the endogenous gene -- or editing the genomic locus itself, which is beyond the technical scope of this work. Likewise, such systems can themselves perturb the localization of the target RNA. Another suggested approach, FISH, is also rife with technical caveats (see, for example: PMID 25555572). Fixation conditions can perturb localization, probe selection and validation can be technically cumbersome, and poorly vetted probes can lead to artefactual signal. Confounding this is that many of the novel RNAs we've identified are expressed at extremely low levels, making FISH quite challenging. Moreover, this analysis is complicated by a pervasive issue in the RNA localization field: the difficulty in comparing imaging and sequencing data (see, for example: PMID 25630241). Certainly, if we had identified abundant RNAs that are massively enriched in both the NLS and KDEL data sets, we would expect a FISH signal that would be highly localized near the lamina. But, it is difficult a priori to predict what the FISH signal of a lowly-expressed species that is modestly--though significantly--enriched at the lamina might appear, especially if this RNA is among the first of its class to be identified. We therefore believe that addressing this question in a robust way would require an extensive analysis that exceeds the scope of the current work. Finally, given the longstanding difficulties in identifying laminar RNAs, the mere generation of a speculative candidate list represents a significant achievement. We present this list as a compelling starting point for future analysis.

> 5\) The analysis of RNAs potentially associated with the nuclear lamina seems problematic. Whereas 14% of the set of nuclear RNAs detected overlap with the ER-associated RNAs, only 6% of the lncRNAs overlap. Thus, the lncRNAs are under-represented in the population of nuclear RNAs that could be associated with the lamina. The caveat that RNAs identified as nuclear may not actually be nuclear further weakens this analysis.

While the reviewer's comments are insightful, we offer the converse perspective on the data presented in [Figure 5D](#fig5){ref-type="fig"} . Namely, since the lamina is generally thought to be a transcriptionally repressive environment, we assume that laminarlocalized RNAs represent a minority of the nuclear-resident transcriptome. Nuclear RNAs are also quite diverse, comprising many classes that are involved in a multitude of functions. Hence, it might be misleading to try and identify laminar RNAs by looking for conspicuous enrichment of a single class of nuclear RNAs (e.g. lncRNAs) within the KDEL dataset. The majority of nuclear lncRNAs may be involved in broadly uncharacterized, non-laminar functions. In support of this, we know of relatively few lncRNAs that are conspicuously laminar. One such RNA, *NEAT1* (PMID: 25630241), is enriched in our KDEL RIP experiment.

Conversely, it may be more instructive to ask, of the KDEL-enriched RNA population, what proportions are also enriched from the nucleus? Looking at the data this way, we observe that, of the 2494 mRNAs enriched in the KDEL dataset, 385 (15%) are also enriched in the nucleus. For many of these RNAs we can further justify nuclear enrichment as a potential byproduct of regulated premRNA processing, as discussed above. However, of the 28 significantly enriched lncRNAs in the KDEL dataset, 11 (39%) are also enriched in the nucleus, a 2.5-- fold higher proportion than that of their mRNA counterparts.

Finally, given the general agreement between the APEX-RIP-derived nuclearcytoplasmic data and those acquired by other methods ([Figure 2E--F](#fig2){ref-type="fig"}, [Author response image 1](#respfig1){ref-type="fig"}), we remain confident that the RNAs identified are nuclear.

![Fractionation-Seq and APEX-RIP recover similar populations of intronic sequences from each compartment.\
A. Both methods quantify the nuclear enrichment and cytosolic de-enrichment of intronic reads (GENCODE hg19) to similar extents. We ascribe the greater number of intronic reads in the APEX pre-enrichment samples--relative to the Fractionation-Seq starting material--to our use of ribosome depletion, rather than poly(**A**) selection, in our starting samples (*methods*). B. Intronic reads exhibit similar subcellular partitioning by each method. Data shown are for all introns with starting RPKM≥1.0 in at least one experimental replicate. The data correlate with a Spearman's r=0.88, *p*-value=0.](elife-29224-resp-fig1){#respfig1}

> 6\) In the third paragraph of the Discussion, and at several other places of the manuscript, the authors make claims such as: \"Compared to fractionation-based technologies, APEX-RIP offers superior accuracy\". This seems like an over-interpretation based on the evidence presented, especially for the analyses of nucleo-cytoplasmic RNA distribution profiles. Firstly, the authors appear to draw this conclusion by comparing APEX-RIP and Frac-seq data from different cell lines (e.g. [Figure 2F](#fig2){ref-type="fig"}). While it is likely that the nucleo-cytoplasmic localization of RNAs may exhibit a high degree of similarity between cell lines, comparison of results generated from the same cell lines would seem important to draw such conclusions.

We agree with the reviewer's critique, and regret the oversight in our original analysis, which relied on nuclear-cytoplasmic RNA-seq data from the NHEK cell line. To address this concern, we have repeated this analysis using data derived from HEK 293T cells (Sultan et al., PMID: 25113896), the same line used in our experiments. While this is a much more reasonable basis for comparison, as the reviewer correctly anticipated, it has not substantially altered the experimental results. Our revised draft now focuses on these analyses.

> Second, the detection of ER mRNAs within the nucleus in Frac-seq data, but not APEX2-NLS samples, could simply underline the ability of the Frac-seq approach to purify and detect pre-mRNAs. Do the authors detect such species within APEX2-NLS RNA-seq dataset? Is read coverage of intronic regions comparable to that observed with nuclear Frac-seq?

We agree with the reviewer and have addressed with further analysis. Specifically, by quantifying intronic reads in the Frac-Seq (Sultan et al.), NLS- and NES-APEX-RIP datasets, we observed that the nuclear-cytoplasmic distribution of pre-mRNAs was nearly indistinguishable between the two methods: relative to whole-cell RNA, intronic reads were enriched in the nuclear compartment, and de-enriched in the cytosol, to similar extents ([Author response image 1A](#respfig1){ref-type="fig"}). Furthermore, when we examined the partitioning of individual species between these compartments, we observed excellent agreement between the two methods (Spearman's r=0.88; *p-*value \~0, [Author response image 1B](#respfig1){ref-type="fig"}). Hence, we conclude that, en masse, APEX-RIP and Frac-Seq are comparable approaches for isolating immature RNA species from the nucleus. This is also reflected in our revised analysis of the presence of ER-proximal RNAs in nuclear datasets, which shows general agreement between the methods ([Figure 2F](#fig2){ref-type="fig"}).

> 7\) The authors provide evidence that APEX-RIP captures RNAs with lower abundances than alternative approaches do, but it would be nice to have some sort of estimate of the limit of detection.

We have addressed this insightful point more robustly in the revised manuscript. Assigning a lower detection limit is often empirical, and absolutely measuring transcript abundances is technically challenging. However, we have tried to approach this problem with some degree of rigor in the revised [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"} , by calculating the expression range that encompasses 95% of the significantly enriched species in each ER dataset. For Frac-Seq and ribosome profiling, this range has a lower limit at 3.7 and 2.06 FPKM, respectively; for APEX-RIP this limit is 0.42 FPKM.

> Furthermore, there is no discussion for any of the experiments about false negatives.

For each experiment, we characterize the coverage, or the recall of expected RNAs. The inverse of coverage is the false negative rate. Hence, if our coverage is 97.1% (for the "gold list" or "true positive list" of 71 mRNAs encoding established ER-resident proteins -- [Figure 4D](#fig4){ref-type="fig"}), then our false negative rate is 2.9% -- the fraction of RNAs our method is expected to miss. We have now clarified this in the text and methods.

> 8\) Regarding RNAseq library preparation and data analysis, it would be useful to include more detail in both the Materials and methods section and the main text to demonstrate that their sequencing datasets and the different reference datasets are indeed directly comparable. Specifically, in the Materials and methods section the authors should include the dataset IDs for the specific ENCODE datasets and explain whether they as well as the other mentioned datasets were generated using comparable library preparation and sequencing methods.

We agree and apologize for the oversight. We have revised the text to include the information in both the Materials and methods section and main text of the manuscript. We furthermore explicitly discuss the differences between this workflow and those used to generate the Frac-Seq and Ribosome Profiling data to which we compare our results, which no longer includes any ENCODE dataset. While the Frac-Seq libraries to which we compare our work were generated through methods comparable to our own, ribosome profiling is substantially different. These differences ultimately mean that ribosome profiling samples a different subset of the transcriptome (i.e.--ORFs within mRNAs). As discussed in the text, we believe that, by analyzing the data at the gene level (and not the transcript, ORF or µORF level), and by examining fold enrichments (which normalize the differences to which each RNA is sampled in a given workflow) rather than absolute abundances, we have accounted for these differences. Moreover, the fact that ribosome profiling and APEX-RIP sample different subsets of the transcriptome-- namely, that APEX-RIP can analyze ncRNAs while ribosome profiling cannot--is part of the message of our work.

> While the authors specifically mention lncRNAs, it is unclear how other, often highly abundant, non-protein coding RNAs were treated in the analysis. While this should be explained in detail in the Materials and methods, it would be useful to also include a brief description in the main text.

As per the reviewer's suggestion, we have expanded the description of our library preparation and analysis workflows, and discuss in both the Materials and methods and main text the caveats to our approach. We enumerate the classes of RNA that may be opaque to our analysis, and why. Furthermore, the data presented in column C of [Supplementary files 1A](#supp1){ref-type="supplementary-material"}, [2A, 2B](#supp2){ref-type="supplementary-material"}, [3A,](#supp3){ref-type="supplementary-material"} and [4B](#supp4){ref-type="supplementary-material"} indicate the GENCODE-defined RNA class of each species analyzed.

> 9\) For IF assays to confirm proper APEX/HRP fusion subcellular targeting, co-labeling with organelle specific markers should be shown.

Based on the reviewer's suggestion, we have now included organelle-specific markers in the revised immunofluorescence [Figures 1B](#fig1){ref-type="fig"}, [3C](#fig3){ref-type="fig"} and Figure1---figure supplement 2. DAPI serves to mark nuclei in [Figures 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"} .

[^1]: Department of Pharmacology, The University of Washington, Washington, United States.

[^2]: Department of Biochemistry, University of Colorado BioFrontiers, Colorado, United States.

[^3]: These authors contributed equally to this work.
